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ADOPTION OF INNOVATION
Abstract
The translation of advances in clinical research into clinical practice in a manner that provides
benefits while reducing potential harm is a challenge within the health care delivery system.

Data from a phase III multicenter clinical trial led to the 2012 US Food and Drug Administration
(FDA) approval of a 90-minute infusion of rituximab (Rituxan) starting at Cycle 2 for patients
with non-Hodgkin’s lymphoma who did not experience a Grade 3 or 4 infusion-related adverse
event during Cycle 1. The 90-minute rituximab faster infusion will result in a significant change
in how nurses in the United States have been administering rituximab since initial FDA approval
15 years ago. This innovative change and its potential impact on patient care demonstrates the
need for evidenced-based approaches that integrate the best current knowledge of rituximab
administration with nursing clinical expertise to help ensure safe and effective resource
utilization when delivering patient care. The aim of this Doctor of Nursing Practice project is to
develop an evidenced-based tool kit to assist oncology nurses in adopting rituximab faster
infusion while maintaining patient safety, achieving benefits in resource utilization, and
promoting both patient and nursing satisfaction. A review of the literature was conducted to
identify existing data and a tool kit was created to enable oncology nurses to conduct 30-day
pilots to assess the real-world impact of rituximab faster infusion on nursing practice, patient
safety, and resource utilization. An interdisciplinary panel of rituximab experts evaluated the
clinical accuracy and overall usefulness of the tool kit and confirmed that components were
clinically accurate and could inform the adoption of rituximab faster infusion by oncology
nurses.
Keywords: rituximab, nursing, innovation, and faster infusion
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Section I: Clinically Relevant Issue
Issue Background and Relevance
Translating scientific innovations into clinical practice in a manner that provides benefits
while reducing potential harm is a challenge within the health care delivery system. The nursing
profession is on the front line of care delivery, and the task of medication administration is an
activity predominately performed by nurses. To incorporate evidenced-based practices into
clinical care and achieve a safer health system, leadership and resources are required.
The complexity involved with administering medications creates opportunities for errors
and potential harm to patients (Wulff, Cummings, Marck, & Yurtseven, 2011). The Institute of
Medicine (IOM) Quality Chasm Report To Err is Human: Building a Safer Health System
(Kohn, Corrigan, & Donaldson, 2000) called national attention to the fact that up to 100,000
people die in hospitals each year as a result of preventable medical errors, including errors in
administering treatment. While the IOM report specifies that achieving safer care must include
three agendas (1) identifying what works (efficacy), 2) ensuring appropriate use, and 3)
delivering it without errors), few patient safety practices examined in the report that healthcare
leaders are working to implement received the “greatest strength of evidence.” This disconnect
may have been driven by the literature analysis methodology used in the IOM report that
prioritized only data from randomized trials (Leape, Berwick, & Bates, 2002). However, the
extended time required for new clinical research evidence to be incorporated into clinical
practice is an obstacle. For oncology, although there have been many advances in the diagnosis
and treatment of cancers, the dissemination and adoption of innovative evidenced-based findings
into nursing practice by clinicians remains a challenge for ensuring quality cancer care (Ousley,
Swarz, Milliken, & Ellis, 2010).
Keith Dawson
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The US Food and Drug Administration (FDA) is the federal agency responsible for
protecting the public health by assuring the safety and effectiveness of human drugs (United
States Food and Drug Administration, 2012). In 1979 the FDA established the black-box
warning system as the strongest labeling requirement for drugs and drug products that can cause
serious adverse events, including death (Halloran & Barash, 2010). The warning provides
information enclosed in a black box to highlight essential information regarding the proper
prescription and monitoring of severe adverse events. A retrospective study conducted to
estimate provider compliance with selected black-box warnings for medications used in the
ambulatory care setting found that while 40% of patients received a drug including a black-box
warning, provider compliance with following these warnings was variable (Wagner et al., 2006).
Adverse drug events (ADEs) are injuries that result from the use of a drug and account
for over 770,000 people being injured or dying each year in hospitals, with resulting costs
reaching $5.6 million each year per hospital (Agency for Healthcare Research and Quality, 2001;
Hughes & Blegen, 2008). Some ADEs are caused by preventable errors, of which approximately
34% occur at the time of medication administration, an error-prone process stage that primarily
involves nurses. A prospective observational study of 107 nurses preparing and administering
intravenous medications in hospitals found that nearly 70% of intravenous administrations had at
least one error, of which 25.5% were serious (Westbrook, Rob, Woods, & Parry, 2011). For
administration errors involving infusion rates, nursing experience played a critical role; serious
errors were lowest among nurses with the most clinical experience. These data suggest that
targeting experienced nurses first is an optimal strategy for testing interventions to reduce error
rates. However, Patient Safety and Quality: An Evidence-Based Handbook for Nurses published
by the Agency for Healthcare Research and Quality (AHRQ) reviewed the research regarding
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medication safety in relation to nursing care and concluded that, while adequate evidence exists
regarding the reporting of medication error, there was a lack of evidence about interventions to
prevent errors from occurring (Hughes & Blegen, 2008). The challenge is that the safe delivery
of patient care requires nursing practices that are consistent with the best available evidence.
When evidence is lacking, nursing scholarship must seek to fill the void.
One area where there is a lack of data being collected is in prospective oncology clinical
trials, where the impact of medication administration on nursing practice has not been routinely
measured (ClinicalTrials.gov, 2012). In such cases, retrospective data collected from nurses may
provide useful insights to inform the development and implementation of practices that support
safer patient care. These data would augment evidence from other sources, such as
pharmaceutical sponsored clinical trials in which medication administration is a component
being studied and research sponsored by AHRQ, whose mission is to improve the quality,
appropriateness, and effectiveness of health care services (Kohn et al., 2000).
Because of the lack of data that are informative, as new innovations are developed that
have an impact on medication administration nurses face a dilemma and must choose to either
adopt these innovations without supporting, usable information or continue to use existing
practices. The aim of this Doctor of Nursing Practice project is to develop an evidenced-based
tool kit to assist oncology nurses in adopting rituximab faster infusion, which is an innovation for
NHL patients, while maintaining patient safety, achieving benefits in resource utilization, and
promoting both patient and nursing satisfaction.
Non-Hodgkin’s Lymphoma (NHL)
The Surveillance, Epidemiology and End Results (SEER) Program of the National
Cancer Institute estimates that 70,130 people in 2012 will be diagnosed with, and 18,940 people
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will die of, non-Hodgkin’s lymphoma (NHL) which are cancers of lymphocytes (white blood
cells). Approximately 484,000 men and women in the United States are living with NHL,
making this the seventh most common cancer in the United States (National Cancer Institute,
2012a). The World Health Organization (WHO) classification divides NHL into types that are
either B-cell origin, T-cell origin, or natural killer (NK)-cell origin (World Health Organization,
2012). Approximately 85 percent of NHL cases are cancerous B-cell origin and include diffuse
large B-cell lymphoma (DLBCL), an aggressive (fast-growing) subtype, and follicular
lymphoma (FL), an indolent (slow-growing) sub-type (National Cancer Institute, 2012b; The
Leukemia & Lymphoma Society, 2012). The incidence of DLBCL and FL are 31% and 22%,
respectively, making these the most common NHL subtypes (Rummel, 2010).
Although no standard therapy exists for the initial treatment of indolent FL, data from a
large longitudinal, observational study reported that 65% of FL patients in the United States from
2004-2007 received a rituximab based initial treatment strategy (Friedberg et al., 2009).
Rituximab (Rituxan) is a CD20-directed cytolytic antibody that was the first targeted cancer
medication approved by the FDA, receiving initial US FDA approval in 1997. Rituximab is an
infused medication and indicated for the treatment of patients with B-cell NHL, including
DLBCL and FL, as well as other indications (Genentech, 2012). Given that infusion reactions
can occur with almost all systemic agents used in cancer treatment (Zetka, 2012), infusion
reactions associated with the most widely used initial treatment strategy for FL patients would be
of interest to clinicians, and specifically to oncology nurses who administer agents like
rituximab.
Rituximab Infusion Related Reactions
The safe administration of medications is an essential element of nursing practice and is a
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core competency to ensure patient safety. The American Society of Clinical Oncology (ASCO)
and the Oncology Nursing Society (ONS) have created chemotherapy safety administration
standards that have been recently revised to add safety measures aimed at reducing timing errors
that can result in patients not receiving the intended amount of chemotherapy (Jacobson et al.,
2012). This builds upon previous standards for chemotherapy preparation and administration
requiring independent verification by a second person of chemotherapy orders, including drug
dose, volume, and rate of administration.
An infusion-related reaction (IRR) is defined as a disorder characterized by adverse
reaction to the infusion of pharmacological or biological substances (Vogel, 2010). Reactions
can range from Grade 1-2 mild transient reactions, when an intervention is either not indicated or
intervention responds promptly to symptomatic treatment (e.g., antihistamines, NSAIDS), to
Grade 3-4 reactions, requiring hospitalization for prolonged clinical sequelae and which can be
life-threatening (United States Department of Health and Human Services, 2010). Monoclonal
antibodies like rituximab can induce B-cell lysis predisposing patients to higher cytokine release
associated with tumor destruction (Vogel, 2010). Additionally, patients with higher numbers of
circulating malignant cells may have an increased risk for infusion reactions due to higher
cytokine release.
Infusion related reactions are among the most common adverse reactions associated with
rituximab and have an incidence rate ≥25%. Infusion related reactions also are included in
rituximab’s label as a black box warning. The warning states that:
•

Fatal infusion reactions within 24 hours of rituximab infusion may occur

•

Approximately 80% of fatal reactions occur with first infusion

•

Monitor patients and discontinue rituximab infusion for severe reactions (Genentech,
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2012).
Until October 2012, the Rituximab (Rituxan®) United States Package Insert (USPI)
recommended 4−6 hour infusion rates for the first infusion and 3−4 hours for each subsequent
infusion (Genentech, 2012; Sehn et al., 2007). These administration times make rituximab a
time intensive medication to administer, requiring nursing time and chair space resources. Recent
data from pilot studies and a large clinical trial (U4391g, aka the RATE study) supported wider
implementation of rituximab with a faster infusion rate (Dakhil et al., 2011). In October 2012,
the US FDA approved a 90-minute infusion for subsequent infusions administered in Cycle 2
through Cycle 6 or 8 with a glucocorticoid-containing chemotherapy regimen for previously
untreated FL and DLBCL patients who did not experience a Grade 3 or 4 infusion related
adverse event during Cycle 1, and who tolerated the 90-minute infusion in Cycle 2. Patients who
have clinically significant cardiovascular disease or who have a circulating lymphocyte count
3

≥5000/mm before Cycle 2 should not be administered the 90-minute infusion. Currently there
is no literature describing the penetration of faster infusion usage in the United States, although
there is evidence that the current adoption rate is approximately 25% and that some institutions
are waiting on more data prior to implementation of this innovative method of administration
(Montez, 2012; Palkhivala, 2007).
Wider implementation of rituximab faster infusion in a non-research patient population
should increase given the recent FDA-approved faster infusion administration guidelines.
Studies of the non-initial administration of rituximab at a faster rate have not demonstrated an
increased risk for Grade 3 or 4 infusion-related reactions (Chiang et al., 2010; Corey, Go, &
Schaper, 2007; Coulter, 2010; Genentech, 2012; Sehn et al., 2007; Swan, Murillo, Cox, Lamoth,
& Baker, 2010). Additionally, data from the RATE trial provides the best available evidence to
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support this change in how rituximab is administered. The RATE study excluded patients with a
circulating lymphocyte count >5,000/µL due to their increased risk of experiencing an IRR.
Patients with clinically significant cardiovascular disease, congestive heart failure, ventricular
arrhythmia requiring medication, or peripheral vascular disease were also excluded from the
RATE study (Dakhil et al., 2011). These exclusions are also included in the October 2012 USPI
regarding 90-minute rituximab administration. Clinicians will need to closely assess these
excluded patients to ensure that rituximab is safely administered via a faster infusion only to
appropriate patients.
Time and labor resources required to administer rituximab according to the current USPI
recommended 90-minute infusion rates may decrease. These time and resource savings may also
result in increases in both patient and nursing satisfaction. This innovative change in drug
administration and the resulting potential positive impacts on patient care demonstrate the need
for evidenced-based approaches that integrate the best current knowledge of rituximab
administration with nursing clinical expertise to help ensure safe and effective resource
utilization when delivering patient care.
Innovation and Nursing Practice
Innovation is “an idea, practice, or object that is perceived as new by an individual or
other unit of adoption.” Two characteristics that determine the rate of adopting an innovation
include 1) relative advantage, the degree to which an innovation is perceived as better than the
idea it supersedes, and 2) compatibility, the degree to which an innovation is perceived as
consistent with the existing values, past experiences, and needs of potential adopters (Rogers,
2003). The American Nurses Association (ANA) Standards of Professional Practice include 1)
integrating current evidence findings into practice (i.e., ideas that can be perceived as “new”) and
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2) utilizing appropriate resources to provide nursing services that are safe, effective, and
financially responsible (i.e., consistent with “existing values”) (American Nurses Association,
2010).
The development, evaluation, and dissemination of patient-centered, evidence-based
interventions that contribute to quality cancer care are central to the practice of oncology nursing
and are goals included in the Oncology Nursing Society’s 2012–2016 Strategic Plan (Oncology
Nursing Society, 2011). A primary focus of the Doctor of Nursing Practice program is on the
translation of new science, its application and evaluation, with the goal of nurses delivering the
highest quality health care (American Association of Colleges of Nursing, 2006). Oncology
nurses face a choice to either adopt the new rituximab administration guidelines or to maintain
current practices. In order to adopt this innovation nurses must first assess the impact that this
change may have on both nursing practice and patient care. Given the potential growth of
rituximab faster infusion with the recent US FDA approval of the 90-minute infusion rate, this is
an important topic for nursing to explore using clinical scholarship.
The translation of scientific advances in clinical research that result in new medications
and methods of medication administration (such as new rituximab infusion guidelines) into realworld clinical practice is a continuing challenge, resulting in gaps in the adoption of new medical
knowledge. Although factors that influence adoption, such as clinicians’ information needs,
ability to assess information, and make changes to their practices have been studied (Carlson,
2008), no studies investigating the innovativeness of nurses and the adoption of evidence-based
practices generated from pharmaceutical company sponsored clinical trials were found in the
literature.
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Results from a survey administered to over 2,800 health care practitioners, including
oncology nurses and physicians, found that although more than 85% of oncology nurses reported
having adequate access to the research they need to keep their practice current, only 34%
reported having adequate time to study and utilize the research. Moreover, 45% of oncology
nurses reported that research findings are often reported in a manner that makes the findings
difficult to implement at the bedside or in the office. Designing effective interventions that are
tailored to the target practitioner audience is proposed as a strategy to assist with the
dissemination and implementation of new research findings (Ousley et al., 2010).
Although the findings from the RATE trial and subsequent US FDA approval support
wider implementation of rituximab faster infusion for patients with previously untreated NHL, it
is critical to identify the prior conditions that influence nurses’ decisions to adopt evidencedbased practices in order to facilitate the implementation of practices by nurses that would both
enhance patient safety and reduce resource utilization. As leaders, nurses need to collaborate
with other members of the heath care team, including the pharmaceutical industry, when
assessing how to best implement innovative practices. Given oncology nurses’ key role in
medication administration, there is an opportunity for nursing to generate evidence where gaps
exist in the literature regarding the adoption of best clinical strategies to deliver medications and
to improve the quality of patient care (Institute of Medicine (IOM), 2010).
To address this gap between research and its use, the psychometric properties of a set of
four instruments were developed and tested to measure conditions influencing nurses’ decisions
to adopt evidenced-based pain management practices, including an Innovativeness Instrument.
The Innovativeness Instrument included six items measuring the factors of leadership and
reliance on others, with Cronbach alpha’s of 0.743 and 0.650, respectively, for these two factors,
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and 0.731 for the total instrument. The Innovativeness Instrument is suggested as a valid method
to identify early adopters of innovation. Early adopters are opinion leaders who evaluate
innovations and encourage implementation of the innovation into local nursing practice (Carlson,
2008; Rogers, 2003).
Pharmaceutical research is a key source of new data providing evidence that may
promote a change in clinical practice. According to the Pharmaceutical Research and
Manufacturers of America (PhRMA), the lobbying organization that represents leading US
pharmaceutical research and biotechnology companies, PhRMA member companies have
invested an estimated $49.5 billion in 2011 in discovering and developing more than 300 new
medicines approved by the US FDA in the last 10 years, making the US biopharmaceutical
research sector a global leader in medical innovation (Pharmaceutical Research and
Manufacturers of America, 2012). However, for all but one of the active NHL clinical trials
recently searched, objectives specific to nursing practice are not included in the clinical trial
design. In September 2012, a search of ClinicalTrials.gov, a registry and results database of
federally and privately supported clinical trials conducted in the United States and around the
world, found 352 open interventional NHL studies recruiting patients in the US. Of these, the
trial entitled “Assessment of Hypersensitivity Reactions and Feasibility of a 60 Minute Rapid
Infusion Rituximab Protocol in Patients with B-Cell NHL and Chronic Lymphocytic Leukemia
(CLL) at a Comprehensive Cancer Center” was the only study that included an objective that
was specific to nursing practice (ClinicalTrials.gov Identifier: NCT01206777). This study is
ongoing and is evaluating both the time savings of a 60-minute infusion versus standard infusion
and the degree of nursing satisfaction as measured with a before and after infusion survey
(ClinicalTrials.gov, 2012).
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Theoretical Framework
The Iowa Model of Evidence-Based Practice to Promote Quality Care (Titler et al., 2001)
was selected as the conceptual model to adopt rituximab faster infusion into nursing practice.
Using the Iowa Model, adopting new medication administration practices is a knowledge
focused trigger related to new findings from both the RATE trial and a review of literature
supporting the administration of rituximab faster infusion for the treatment of appropriate
patients with NHL starting at Cycle 2, Day 1. This trigger would be a priority for any practice
setting administering rituximab since it has implications for safe medication administration
(nursing practice), nursing/patient satisfaction, and resource utilization. Even with US FDA
approval of a new 90-minute faster infusion rate, nurses may question if the faster infusion is
safe, given a long history of administering rituximab at a standard infusion rate.
If adopting rituximab faster infusion is a priority for a practice setting, a team that includes
infusion nurses, clinical trial nurses (if applicable), clinical nurse specialists, and unit
managers/educators should be formed, along with clinical pharmacists and prescribing
physicians, to critique and synthesize existing research for use within practice settings. The
available literature regarding rituximab faster infusion supports piloting the change in practice
settings where there is little to no experience with this alternative method of rituximab
administration. After completion of a practice-setting, pilot with outcomes supporting safety,
resource utilization, and nurse/patient satisfaction benefits, rituximab faster infusion can be
implemented within practices as long as outcomes are monitored for continued quality
improvement.
Innovation is an idea, practice, or object that is perceived as new by the adopters.
Diffusion is the process in which an innovation is communicated through certain channels over
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time among members of a social system. Roger’s Diffusion of Innovations model was selected
as the strategy to facilitate the successful adoption of rituximab faster infusion. Attributes of
innovations impact their rates of adoption by the social system. Perceived attributes of
innovation, including relative advantage and complexity, can determine the rate of an
innovation’s adoption (Rogers, 2003). For this project, rituximab faster infusion is the
innovation perceived as new to oncology nurses.
Definition of Key Terms
The following are key terms used in this project:
•

Adverse Drug Reaction (ADR): A significant ADR is any unexpected, unintended,
undesired, or excessive response to a drug that 1) requires discontinuing the drug
(therapeutic or diagnostic), 2) requires changing the drug therapy, 3) requires
modifying the dose (except for minor dosage adjustments), 4) necessitates admission
to a hospital, 5) prolongs stay in a health care facility, 6) necessitates supportive
treatment, 7) significantly complicates diagnosis, 8) negatively affects prognosis, or
9) results in temporary or permanent harm, disability, or death (American Society of
Health-System Pharmacists, 1995).

•

Black Box Warning: US Food and Drug Administration's strongest labeling
requirements for high-risk medicines. Rituximab (Rituxan®) includes a Black Box
Warning for Infusion Reactions (Wagner et al., 2006).

•

Innovation: An idea, practice, or object that is perceived as new by an individual or
other unit of adoption (Rogers, 2003).
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Infusion-related reaction (IRR): A disorder characterized by adverse reaction to
the infusion of pharmacological or biological substances (United States Department
of Health and Human Services, 2010).

•

Medication Errors: Any preventable event that may cause or lead to inappropriate
medication use or patient harm while the medication is in the control of the health
care professional, patient, or consumer. Such events may be related to professional
practice, health care products, procedures, and systems, including: prescribing; order
communication; product labeling, packaging, and nomenclature; compounding;
dispensing; distribution; administration; education; monitoring; and use (National
Coordinating Council for Medication Error, 2012).

•

Rituximab Faster Infusion: Non-initial rituximab administration that is planned for
a 90-minute duration (Genentech, 2012).

•

Rituximab Standard Infusion: Initial and subsequent rituximab administrations
according at an infusion rate > 90 minutes as follows:
o DO NOT ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS
o Pre-medicate before each infusion and administer only as an intravenous (IV)
infusion
o First Infusion: Initiate infusion at a rate of 50 mg/hr. In the absence of
infusion toxicity, increase infusion rate by 50 mg/hr increments every 30
minutes, to a maximum of 400 mg/hr.
o Subsequent Infusions: Initiate infusion at a rate of 100 mg/hr. In the absence
of infusion toxicity, increase rate by 100 mg/hr increments at 30-minute
intervals, to a maximum of 400 mg/hr.
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Interrupt the infusion or slow the infusion rate for infusion reactions.



Continue the infusion at one-half the previous rate upon improvement
of symptoms.

•

United States Package Insert (USPI): Prescribing information, also called product
information, product labeling, or the package insert ("the PI"). Content is generally
drafted by the drug manufacturer and approved by the US FDA. It includes the
details and directions healthcare providers need to prescribe the drug properly.

Assumptions and Limitations
Assumptions include that only registered nurses completed the survey and that the sample
is representative of oncology nurses who typically administer chemotherapy infusions.
However, the survey used a convenience sample of oncology nurses based on available email
lists, which may have added bias to survey responses. Therefore, survey results should be
interpreted with caution. Limitations of this project include that data were collected
retrospectively and those nurses who participated in the RATE trial were surveyed
approximately 4 years after the RATE protocol was initially finalized. Patient satisfaction and
quality of life assessments were not within the scope of the survey. The survey was completed
by convenience sample of 25 survey responders and data were not stratified by RATE study
participation versus clinical practice adoption of rituximab faster infusion. Data findings may
vary with a larger responding sample.
Project Goals and Expected Outcomes
The PICO evidenced-based decision-making process was used to define the patient
population, intervention, comparison group, and expected project outcomes. The PICO
evidenced-based decision-making process for rituximab faster infusion is the following:
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• P: Patient Population: Patients age ≥ 18 years previously untreated NHL who are
scheduled to receive treatment with rituximab.
• I: Intervention: Starting at Cycle 2, administer rituximab 90-minute infusion to NHL
patients who did not experience a Grade 3 or 4 IRR during Cycle 1. Patients with
clinically significant cardiovascular disease and high circulating lymphocyte counts ≥
5000/mcL are not recommended to receive the faster infusion.
• C: Comparison: Starting at Cycle 2, administer rituximab infusion at a rate of 100 mg/hr.
In the absence of infusion toxicity, increase rate by 100 mg/hr increments at 30-minute
intervals, to a maximum of 400 mg/hr.
• O: Outcomes: Safety, Resource Utilization, and Nursing Practice Impact.
o Safety: Incidence at clinical site/institution of Grade 3 or 4 IRRs at Cycle 2 and
beyond.
o Resource Utilization:
a) Infusion chair turnover: # chemotherapy infusions, including rituximab
infusions, per chair within 30-day period (pre and post pilot).
o Nursing Practice Impact: As measured by positive “Overall Impression” scores
≥ 90%. Nurse survey responses Questions 27-30. Question 27 (impression),
Question 28 (recommend to patients), Question 29 (safety), Question 30 (patient
preferences).
The goal of this project is to develop an evidenced-based tool kit to support oncology
nurses’ adoption of rituximab faster infusion. By developing this tool kit, the expected outcomes
are that rituximab faster infusion will be adopted so that patient safety is maintained while
achieving both resource utilization and patient and nursing satisfaction benefits.
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Section II: Review of the Evidence
A review of literature accessing the MEDLINE and CINAHL Plus databases with the
keywords rituximab, infusion reactions, nursing, evidence, and rapid/faster infusion was
undertaken seeking to answer the following question:
What evidence exists regarding the safety of administrating rituximab faster infusion and the
impacts of this innovation on nursing practice and resource utilization?
Data Synthesis
Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (United States
Department of Health and Human Services, 2010) defines infusion-related reactions as “a
disorder characterized by adverse reaction to the infusion of pharmacological or biological
substances” (see Table 1). The incidence of rituximab infusion-related toxicity is highest with the
first infusion (77%) and decreases with subsequent infusions (30% with the fourth infusion, 14%
with the eighth infusion). For fatal reactions, approximately 80% occur with the first infusion,
with typical onset between 30 and 120 minutes. Rituximab-induced infusion reactions and
sequelae include urticaria, hypotension, angioedema, hypoxia, bronchospasm, pulmonary
infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation,
cardiogenic shock, anaphylactoid events, or death (Genentech, 2012).
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Table 1
Common Terminology Criteria for Adverse Events (CTCAE): Infusion Related Reactions

Adverse
Event
Infusion
related
reaction

General disorders and administration site conditions
Grade
1
2
3

4

5

Mild transient
reaction;
infusion
interruption not
indicated;
intervention not
indicated

Therapy or
Prolonged (e.g., LifeDeath
infusion
not rapidly
threatening
interruption
responsive to
consequences;
indicated but
symptomatic
urgent
responds
medication
intervention
promptly to
and/or brief
indicated
symptomatic
interruption of
treatment (e.g., infusion);
antihistamines, recurrence of
NSAIDS,
symptoms
narcotics, IV
following initial
fluids);
improvement;
prophylactic
hospitalization
medications
indicated for
indicated for
clinical sequelae
<=24 hrs
Definition: A disorder characterized by adverse reaction to the infusion of pharmacological or
biological substances (United States Department of Health and Human Services, 2010).

Although rituximab is generally well tolerated, there are patients who have
allergic/anaphylactic reactions and patients who experience infusion reactions believed to be due
to cell destruction and the release of cytokines (Breslin, 2007). Either IgE or non-IgEdependent mechanisms have been suggested as possible etiologies for infusion reactions to
monoclonal antibody therapy. Additionally, administration of a monoclonal antibody like
rituximab, which can induce B-cell lysis, predisposes patients to have higher cytokine release
associated with tumor destruction. Patients with a higher number of circulating malignant cells
may have an increased risk for infusion reactions associated with higher cytokine release as well.
Patients experiencing allergic/anaphylactic reactions should never be re-challenged. However,
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patients who have a cytokine release reaction, rather than a true allergic type 1 hypersensitivity
reaction, may be re-challenged with rituximab after accurate assessment and documentation of
the infusion reaction (Chung, 2008). Strategies to address potential infusion reactions—such as
fractionated dosing of rituximab (i.e., split first dose over two days) and hospitalization—have
been used for patients at high risk for cytokine release (Vogel, 2010). In addition, premedication
with antihistimines, acetaminophen, and/or corticosteroids are common practices to prevent
infusion reactions related to monoclonal antibody therapy (Chung, 2008; Genentech, 2012).
Supportive care (i.e., glucocorticoids, epinephrine, bronchodilators, oxygen) is also instituted as
needed for infusion reactions. Additional intervention includes slowing the infusion rate,
interrupting the infusion, or permanently discontinuing rituximab, depending on the severity of
the infusion reaction (Genentech, 2012).
To minimize the potential for infusion-related toxicity, the USPI recommends that, in
addition to premedication with an antihistamine and acetaminophen, initiating the first infusion
at a rate of 50 mg/hr and, in the absence of infusion toxicity, increasing the infusion rate in 50
mg/hr increments every 30 minutes to a maximum of 400 mg/hr. Subsequent infusions should
start at a rate of 100 mg/hr and, in the absence of infusion toxicity, be increased by 100 mg/hr
increments every 30 minutes to a maximum of 400 mg/hr. In the event of an infusion reaction,
the infusion should be interrupted or slowed and then continued at one half the previous rate
upon improvement of symptoms (Genentech, 2012).
For patients with NHL, the majority of infusion-related adverse events typically occurred
within 30–120 minutes of beginning the first infusion. As noted previously, slowing or
interrupting the rituximab infusion and administering supportive care were effective
interventions in resolving the infusion reactions. After symptoms have resolved, the infusion
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may be resumed at a minimum 50% reduction in the infusion rate. Patients with pre-existing
cardiac or pulmonary conditions, those with prior cardiopulmonary adverse reactions, and those
with high numbers of circulating malignant cells (≥25,000/mm3) should be closely monitored
(Genentech, 2012). Even with pre-treatment, patients can have severe infusion related reactions.
In a retrospective chart review of 19 community oncology practices, severe infusion reactions for
47 patients treated with rituximab (64% diagnosed with NHL) were identified. Approximately
75% received pre-treatment, with acetaminophen, antihistamine, and corticosteroids being the
most common medications given, at 61%, 55%, and 21%, respectively. The majority of severe
infusion reactions occurred during the first cycle of therapy. Post-infusion reaction management
typically included corticosteroids, oxygen, and intravenous fluids. The incidence of
hospitalization after infusion reactions was 5% for Grade 3 infusion reactions and 83% for Grade
4, with a mean of two days in the hospital for Grade 3 and five days for Grade 4 reactions
(Schwartzberg, Stepanski, Fortner, & Houts, 2008).
Given rituximab’s long infusion duration and data indicating that approximately 80% of
fatal infusion reactions occur with the first infusion, several pilot studies have investigated the
feasibility and safety of 90-minute rituximab infusion administration times after the first infusion
(Chiang et al., 2010; Corey et al., 2007; Coulter, 2010; Sehn et al., 2007; Swan et al., 2010;
Zahrani, Ibrahim, & Eid, 2009). The protocols required that 1) patients received their first
rituximab infusion according to the USPI, 2) premedication with at least acetaminophen and
diphenhydramine prior to the subsequent faster infusion, and 3) the inclusion of a steroid if the
chemotherapy regimen required a corticosteroid. For subsequent infusions, rituximab was
infused using fixed-volume of 250 mL of normal saline preparation with a maximum

Keith Dawson

ADOPTION OF INNOVATION

23

concentration of 4 mg/mL, with a rate titrated to deliver 50 mL (20%) over 30 minutes followed
by 200 mL (80%) over 60 minutes (Sehn et al., 2007).
The first report of rituximab faster infusion in the nursing literature was at the 32nd Annual
Oncology Nursing Society Congress in 2007 (Corey et al., 2007). The lead author reported
treating 46 patients with 135 infusions (mean 3 infusions) with no Grade 3 or 4 infusion-related
reactions and, based on these findings, concluded that the 90-minute infusion was safe in the
treatment of NHL and well tolerated for patients studied in the community setting. However, the
need for additional studies was recognized prior to implementing the 90-minute faster infusion as
standard practice at US sites (Palkhivala, 2007).
A prospective study of 79 patients was conducted at an ambulatory cancer center in
Singapore with CD20-positive NHL to assess whether the non-initial rituximab dose can safely
be administered as a faster 90-minute infusion and to study the impact of a faster 90-minute
infusion on resource utilization. Nurses were given detailed administration instructions, patients
were pre-medicated with diphenhydramine and paracetamol (acetaminophen), and, if oral
corticosteroids were part of the patient’s chemotherapy regimen, the day-1 dose of
corticosteroids were only administered after the rituximab infusion was complete, in order to
avoid masking any potential infusion-related reactions. The study found that rituximab faster
infusion was well tolerated with no Grade 3 or 4 infusion-related adverse events (Chiang et al.,
2010).
A prospective study of 13 patients at outpatient and inpatient oncology units with CD20positive B-Cell malignancy, with or without steroid-containing chemotherapy, was conducted to
assess if the non-initial rituximab dose can safely be administered at a faster 90-minute infusion
rate. All patients received acetaminophen and diphenhydramine premedication; no symptomatic
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infusion reactions were observed in 12 patients, while one patient experienced a Grade 3 infusion
reaction (nausea, vomiting, syncope) on the second faster-rituximab infusion. A retrospective
chart review of 100 patients was also conducted for patients receiving rituximab according to the
USPI recommendations. This review found that infusion reactions were experienced by 34% of
patients, and that there was an increased risk of infusion reactions for inpatients versus
outpatients (23.1% vs. 12.5%; P <0.03) (Swan et al., 2010).
An examination of the safety of rituximab faster infusion for 150 NHL patients with a
corticosteroid-containing chemotherapy regimen who received 473 rituximab faster infusions
and 56 NHL patients receiving 92 rituximab faster infusions as maintenance therapy found no
Grade 3 or 4 infusion-related reactions. In addition, more than 1,200 patients in Canada have
received rituximab faster infusion with only one Grade 3 infusion reaction reported. These
findings led to the adoption of the 90-minute faster infusion schedule throughout the province of
British Columbia (Sehn et al., 2007).
In addition, a systematic review of the literature has been conducted to examine evidencebased data related to the safety of rituximab faster infusion in adult NHL and CLL patients. Data
from experimental and non-experimental studies were critically appraised by two independent
reviewers for methodological validity (Lang, Hagger, & Pearson, 2011). A meta-analysis of nine
studies that included 559 NHL patients who completed 1,799 cycles of a rituximab 90-minute
infusion found 2.6% (n=12) acute adverse reactions. Of those reactions, using CTCAE criteria,
seven were Grade 1, five were Grade 2, and no Grade 3 or 4 acute adverse reactions were
reported. While the Lang et al. systematic review supports a finding of faster rituximab infusion
over 90 minutes as a safe practice for NHL patients, it calls for more research and detailed
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analysis to develop more specific guidelines, including dosage for antipyretics (i.e.,
acetaminophen, antihistamine, and corticosteroids).
The RATE trial enrolled approximately 451 patients at 100 centers in the United States.
The primary objective of this study was to determine the incidence of Grade 3 or 4 infusionrelated reactions resulting from faster infusion of rituximab in patients who have previously
received rituximab at the standard infusion rate without experiencing a Grade 3 or 4 infusionrelated adverse event (Clinicaltrials.gov, 2011). Patients received the faster infusion (rituximab
administered over 90 minutes) in Cycle 2 and, if tolerated, in all subsequent cycles. A total of
363 patients who had not experienced a Grade 3 or 4 IRR while receiving rituximab in
combination with chemotherapy during Cycle 1 were evaluated. The incidence of Grade 3 or 4
IRRs was 1.1% at cycle 2 and 2.8% during cycles 2–8, with no fatal IRRs or fatal AEs on days
1–2 at any cycle in this study (Dakhil et al., 2011). Results from this study confirmed that the
90-minute infusion schedule for rituximab is both safe and feasible in NHL patients.
Data from the RATE trial led to the October 19, 2012 US FDA approval of a 90-minute
infusion for rituximab starting at Cycle 2 for patients with NHL who did not experience a Grade
3 or 4 infusion-related adverse reaction during Cycle 1. Patients with clinically significant
cardiovascular disease and high circulating lymphocyte count greater than or equal to 5000/mcL
are not recommended to receive the faster infusion. The RATE trial results are comparable to
the results of IRRs during Cycle 2 reported from trials using the standard infusion regimen
(Genentech, 2012).
However, FDA approval does not in itself guarantee safe adoption of the new faster
infusion rate in real-world clinical practice. Identifying evidenced-based practices to improve
patient care and increasing efficiency while managing costs are major issues facing the US health
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care system (B. Fortner & Viale, 2009; United States Department of Health and Human Services,
2011). For oncology, this challenge is particularly illustrated by the need to assess new data
regarding the feasibility and safety of non-standard methods of immunochemotherapy
administration that could impact patient outcomes and resource utilization.
The nursing profession has a critical role in the delivery of quality care for patients.
Nurses are seen as partners, educators, advocates, and leaders in cancer prevention, treatment,
and symptom management. Developing, evaluating, and disseminating patient-centered,
evidence-based interventions that contribute to quality cancer care are central to the practice of
oncology nursing and are goals included in the Oncology Nursing Society’s 2012–2016 Strategic
Plan (Oncology Nursing Society, 2011).
Potential benefits of a faster infusion schedule include the following: reduced infusion
times that may in turn provide patients with more scheduling flexibility; improved scheduling
efficiency for infusion center chair time; and more nursing time available for other activities
(Corey et al., 2007; Swan et al., 2010). A retrospective chart review of 100 patients found that
longer infusion time results in longer clinical visits and lengthier utilization of nursing resources.
Faster infusion rituximab was 1.7 hours shorter than standard infusion time for the non-initial
infusion. Patients were surveyed after their first faster infusion and indicated a preference due to
the shortened clinic visits. Although the authors state that nursing staff also preferred the fasterrituximab infusion approach, no survey data were reported in the discussion. The authors
caution that adoption of a faster administration protocol “will succeed only if supported by the
nursing staff,” and that strong nursing leadership and educational in-services highlighting faster
rituximab infusion trial safety data contributed to the “support and comfort” required by nursing
staff to administer this protocol. The nursing staff was credited with achieving the goal of
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decreasing patient time in the infusion clinic through such means as ensuring that premedication
was given and that the faster infusion was started in a timely manner (Swan et al., 2010).
Chiang and colleagues (Chiang et al., 2010) reported a “substantial” reduction in resource
utilization as measured by reduced facility charges to patients and by savings from faster
infusion chair times compared to chair times needed to administer rituximab according to
manufacturer recommendations. Implications for nursing include the need to educate patients
about relevant rituximab infusion-related reactions so that patients may report these reactions to
clinical staff during infusions and possibly prevent a more severe reaction. Given the findings
related to patients experiencing post-infusion nausea and vomiting, nursing researchers may want
to consider studying the incidence of this adverse event in the context of faster-infusion
rituximab and assessing prevention interventions.
As has been noted, evidenced-based recommendations for a 90-minute rituximab faster
infusion in the non-initial administration for NHL patients have implications for nursing practice.
The briefer administration of a 90-minute infusion, the documented safety profile, and improved
resource utilization due to a 50% reduction in nursing workload were reported as advantages of
faster infusion. For patients the faster infusion led to less time in clinic and improved patient
satisfaction (Sehn et al., 2007). Owing to the shorter duration, the amount of nursing time
required for infusion-related monitoring of symptoms and vital signs was reduced (Lang et al.,
2011).
With regard to monitoring, few publications report on either the type or frequency of
monitoring for adverse events that may occur during infusions. In the community setting, one
study found that among 16 patients treated with 51 faster infusions there were no reported Grade
3 or 4 infusion reactions (Coulter, 2010). Patient monitoring included blood pressure, heart, and
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respiratory rates before the infusion and at 15, 30, 60, and 90 minutes. Temperature was
monitored prior to the infusion, and patients were questioned about adverse reactions throughout
the infusion and during each visit. Total infusion time saved (compared to standard rituximab
infusions) was 57 minutes per infusion, with both high nursing and patient satisfaction surveys
scores reported. One outlier was that nurses had concerns that the intense monitoring schedule
used in this study took up the equivalent amount of nursing resources as a standard rituximab
infusion. More research is needed focusing on the experiences and perceptions of nurses
implementing an evidenced-based monitoring schedule for patients receiving faster infusion
rituximab.
The management of infusion-related reactions is a major challenge for nurses when caring
for patients receiving monoclonal antibodies. Although monoclonal antibodies used in oncology
care are generally well tolerated, a major complication with monoclonal antibodies is the
development of mild to life threatening infusion reactions (Carney & Ollom, 2008). In a
retrospective study conducted in collaboration with primary care providers, nurses were able to
minimize infusion reactions by evaluating quality assurance performance metrics for infusion
reactions. The goal of the study was to decrease the number of infusion reactions patients
experienced by developing re-challenge programs for patients receiving paclitaxel and
carboplatin regimens in the outpatient setting (Huddleston et al., 2005). Tracking quality metrics
may be a useful strategy to apply in assessing infusion reaction rates in NHL patients.
Although nurses are recognized as being integral to the management of hypersensitivity
reactions, there are limited data regarding the tasks and associated costs that infusion reactions
require of patients, caregivers, and providers. A review of the literature examining the specific
burden that infusion reactions associated with monoclonal antibodies have on these groups found
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that, overall, tasks required to manage infusion reactions fell into categories that align with

CTCAE grading criteria (see Table 2). Standing orders or protocols and staff education related
to infusion reactions were identified as two strategies to assist nursing staff in managing
reactions (B. Fortner & Viale, 2009).
Table 2
IRR Grade, Human Resource Tasks, Time & Costs
Infusion
CTCAE version 4.03
Related
Definition 9
Reaction
(IRR) Grade

Grade 1 IRR

Grade 2 IRR

Grade 3 IRR

Grade 4 IRR
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Mild transient reaction;
infusion interruption not
indicated; intervention
not indicated
Therapy or infusion
interruption indicated
but responds promptly
to symptomatic
treatment (e.g.,
antihistamines,
NSAIDS, narcotics, IV
fluids); prophylactic
medications indicated
for =24 hrs
Prolonged (e.g., not
rapidly responsive to
symptomatic medication
and/or brief interruption
of infusion); recurrence
of symptoms following
initial improvement;
hospitalization indicated
for clinical sequelae
Life-threatening
consequences; urgent
intervention indicated

Human Resource Tasks,
Time (Minutes) and
Increased Costs
Required to Manage
Patients Experiencing
IRRs (B. Fortner &
Viale, 2009)
Mild IRR not requiring
discontinuation
Tasks: 13, Time: 72
Costs (USD): $51

Rituximab (N=90)
Mean±
±SD Human
Resource Time
(Minutes) and Costs
Accrued for IRR
(Schwartzberg et al.,
2009)
N=30
Time: 262.3 ± 64.4
Costs (USD): $79.4 ± 31.0

Severe IRR
discontinuation of
infusion therapy but
managed in the outpatient
setting
Tasks: 20, Time: 139
Costs (USD): $102

N=5 requiring
Time: 200.2 ± 152.8
Costs (USD): $117.8 ±
60.9

Severe IRR resulting in
hospitalization
Tasks: 22, Time: 106
Costs (USD): $134
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Several studies have examined the economic and human resource impact of infusion
reactions. In the solid tumor setting, a large United States database that includes patient-level
medical and pharmacy claim histories for commercially insured US patients was used to study
the clinical and economic impact of infusion reactions on patients with colorectal cancer (CRC)
treated with the chimeric antibody cetuximab. A key objective of this study was to quantify the
economic burden associated with the management of infusion reactions. The study found that
among CRC patients treated with cetuximab 8.4% experienced infusion reactions that required
resource-intensive medical interventions, and more than two-thirds of patients with infusion
reactions experienced disruptions in their treatment regimen resulting in significant increases in
associated costs. This study’s methods may have utility in assessing the clinical and economic
impacts of infusion reactions associated rituximab faster infusion in patients with NHL (Foley et
al., 2010).
Because of a lack of literature pertaining to systematic examination of the drivers of costs
associated with administering alternative chemotherapy protocols, de Raad and colleagues (de
Raad J. et al., 2010) conducted the first study from a nursing perspective about the time required
to perform chemotherapy-related tasks. Focus groups and a survey were used to assess the
extent to which evidence-based chemotherapy protocols in Australia accurately capture
chemotherapy-related administration tasks and the associated required nursing resources. Patient
education, patient assessment (including assessment for infusion reactions), chemotherapy
administration, and patient communication were the specific nursing activities assessed. On
average, patient education during the first infusion required the most nursing time, followed by
patient communication, administration, and patient assessment, with an average of 3.3 hours of
staff time required per patient visit. Although details regarding time resources associated with
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specific chemotherapy regimens were not described, this information may be used to inform
healthcare decision makers—including nursing leaders—about the amount of nursing time
required to administer chemotherapy and to make an assessment of the cost-effectiveness of
alternative chemotherapy administration protocols.
Time and motion studies have been conducted to examine the human resource
implications of infusion reactions (B. V. Fortner, Schwartzberg, Stepanski, & Houts, 2007;
Schwartzberg et al., 2009). Severe infusion reactions are intensive events that present significant
challenges for patients in the outpatient setting and for oncology practice resource utilization and
workflow (Schwartzberg et al., 2008). Schwartzberg and colleagues (Schwartzberg et al., 2009)
conducted a prospective multicenter time and motion study of patients receiving their first
outpatient infusion of cetuximab or rituximab. Staff time and costs were estimated for the
management of infusion reactions. It was found that 41.3 minutes more staff time was required
for patients who experienced infusion reactions to rituximab; in mean human resource costs this
calculated to a range of $54 to $118. Since awareness can lead to better planning for responding
to infusion reactions in the outpatient setting, identifying clinical guidelines for intervention and
management was suggested by the authors as a way to reduce time spent on managing infusion
reactions effectively.
Only a few studies have explored the impacts of nursing attitudes or interventions and/or
patient education on infusion reactions. A qualitative, interviewer-administered, 31-item survey,
with a convenience sample of 202 oncology nurses attending the 2005 Oncology Nursing
Society’s annual congress, assessed the impact of infusion reactions on both nurses and patients.
The survey found that 96% of nurses reported that Grade 3 and 4 reactions were “very” or
“extremely” disruptive for patients, and 80% felt that these same reactions were also disruptive
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for nursing practice. Moreover, 95% agreed with the statement that “infusion reactions can
result in lost time and increased patient anxiety,” with a statistically significant difference of
more outpatient nurses agreeing or strongly agreeing with this statement (98% versus 90%, P≤
.05). Almost all nurses (98%) agreed that infusion reactions take time away from other patients,
and two-thirds agreed with the statement “infusion reactions add a tremendous amount of stress
and anxiety to the entire staff.” Although this survey was limited by nurses having to
retrospectively self-report on the severity of infusion reaction grade rather than use actual
grading and frequency from chart reviews, it was the first study conducted to examine the impact
of infusion reactions on nurses and patients (Colwell et al., 2007).
Oncology nurses’ perceptions and experiences regarding the involvement of patients in
the prevention of chemotherapy errors have also been explored. A small qualitative descriptive
study of 11 oncology nurses in Switzerland found that although patient participation in safety
was perceived as a complex learning process, oncology nurses reported positive attitudes and
experiences with engaging patients in safety education (Schwappach, Hochreutener, & Wernli,
2010). This finding would need to be studied in US oncology care settings, with a modified
design exploring the impact on patient outcomes of nurses’ perceptions and strategies associated
with educating patients about infusion reactions and about the need for early reporting of
symptoms.
In a related survey of 325 ambulatory office nurses, those surveyed perceived that their
interventions influenced patient outcomes; with regard to satisfaction and patient education, all
respondents reported that they increased patient and family satisfaction either “frequently” or
“sometimes,” and 94% classified patient education on treatment and related side-effects as a
“very important” registered nurse (RN) responsibility. Concerning safety, 97% felt it was “very

Keith Dawson

ADOPTION OF INNOVATION

33

important” that a staff RN administer IV medications, and while 88% reported having a policy
for hypersensitivity reactions, 84% responded that they actually document patient tolerance to
chemotherapy administration. With regard to patient scheduling, an interesting finding was that
although only 41% of staff RNs had the primary responsibility for infusion room scheduling,
54% were responsible for fixing scheduling problems and 61% felt that infusion room
scheduling was a “very” or “somewhat” important RN responsibility (Ireland, DePalma,
Arneson, Stark, & Williamson, 2004). Recommendations based on the survey findings that
could impact patient outcomes include developing a standard guide for chemotherapy
documentation.
One strategy to avoid delayed responses and improve outcomes is for nurses to educate
both patients and family members about infusion reactions and encourage them to report
reactions immediately to clinicians (Vogel, 2010). This family-focused intervention may serve
both to improve a patient’s anxiety and to prevent delayed response times to infusion reactions.
However, more data are needed to assess effectiveness.
The goal of this review of the literature was to identify existing data that may support
implementation of evidenced-based approaches to improve nursing care and outcomes for
patients with NHL receiving rituximab faster infusion in the United States. The findings from
the RATE trial support wider implementation of rituximab faster infusion for patients with
previously untreated NHL. However, there remains a lack of data regarding the impact of
rituximab faster infusion on nursing practice and resource utilization, and in particular on
evidenced-based interventions delivered by oncology nurses to minimize adverse events and
improve patient outcomes. As leaders, nurses need to collaborate with other members of the care
delivery team, which includes the pharmaceutical industry, when making decisions regarding
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adopting innovative strategies that impact patient care. Moreover, evidence that both leadership
and reliance on others are factors that help determine which nurses may be early adopters of
innovations will help inform strategies to support the diffusion of innovation into practice
(Carlson, 2008). The review of literature findings calls for additional data to fill data gaps
related to how changes in drug administration impacts the approaches to care nurses provide to
patients.
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Section III: Implementation Plan
In order to identify potential evidenced-based nursing practices to improve the delivery of
patient care, in March 2012 a draft survey was created with questions derived from the literature
(Carlson, 2008; Colwell et al., 2007; Coulter, 2010; Huddleston et al., 2005; Schwappach et al.,
2010; Vogel, 2010) and combined with questions adapted from a global pharmaceutical
company’s survey of nurses regarding an alternative subcutaneous method to administer
rituximab. In April 2012, to obtain instrument face validity for the clinical component of the
survey, the draft survey was sent to an expert group of 13 nurses who work in the Medical
Science Liaison role within US Medical Affairs for a large global pharmaceutical company.
These scientific professionals specialize in oncology and work in collaboration with health care
professionals to support of the pharmaceutical company’s overall scientific and clinical goals.
After the clinical validity was established based on 11 completed responses (85% response rate)
as well as discussions with DNP committee chair, broader questions originally designed to assess
mental health provider openness to innovation were replaced with questions targeted specifically
to nursing practice about conditions that influence nurses’ adoption of evidence-based practices.
These questions, from Carlson’s Innovativeness Instrument (Carlson, 2008), were obtained
following a search of the CINAHL database using the key words evidenced-based practice,
instrument, and nursing.
In September 2012, after receipt of an exemption from University of San Francisco,
Institutional Review Board for the Protection of Human Subjects (IRBPHS), a letter that
included both appropriate informed consent documentation and a SurveyMonkey ™ link to a 30item questionnaire was sent via email to selected US nurses. (SurveyMonkey ™ is a web-based
survey tool that sends survey responses over a secure, encrypted connection). The objectives of
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the survey were to obtain evidence about oncology nurses attitudes about innovation, their
readiness to adopt new evidenced-based ideas/practices, and their perceptions regarding the
impact of rituximab faster infusion on nursing practice, safety, patients, and resource utilization
Two groups of US oncology nurses were surveyed. First, on September 6, 2012 an email
was sent to 69 active email addresses of Study Coordinators/Study Nurses who participated in
the prospective, open-label, multicenter, single-arm clinical trial designed to assess the safety of
faster infusion of rituximab in previously untreated NHL patients (RATE study). Second, on
September 8, 2012 an email was sent to 72 active email addresses of oncology nurses who
participated in the Oncology Nursing Society's (ONS) Chemotherapy (CHE) and
Ambulatory/Office Nursing (AON) Special Interest Groups (SIG). (Email addresses were culled
from the ONS May 3, 2012 SIG meeting minutes that included email addresses for SIG meeting
attendees.) The RATE Study Coordinators/Study Nurses email addresses were selected because
of their experience administering rituximab faster infusion in the RATE clinical trial; the ONS
SIG email addresses were selected because of an assumption that their self identified clinical
interests would increase the likelihood that they would have previously administered rituximab
faster infusion. The survey was sent to a total of 141 active email addresses for both groups; a
total of 25 surveys were returned between September 6, 2012 and September 21, 2012 generating
an 18% response rate.
The survey included 5 sections and 30 items: 1) Demographics (4 items); 2) Innovativeness
Instrument (6 items, 2 factors: Leadership and Reliance on others); 3) Rituximab Experience (3
items); 4) Impact of Rituximab Faster Infusion on Nursing Practice (13 items); 5) Overall
Impression (4 items) (see Appendix C). Expected outcomes of the survey were to learn more
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about oncology nurses’ attitudes about innovation and their perceptions regarding the impact of
rituximab faster infusion on patient safety, nursing practice, and resource utilization.
Demographics
The background and demographic characteristics of the 25 nurse respondents are presented
in Table D1. Most had a Bachelor’s degree (68.0%) as their highest degree received and have
been practicing nursing for greater than 15 years (72.0%). These nurses worked in both inpatient
(16.0%) and outpatient (32.0%) settings and at both academic (20.0%) and community hospital
(20.0%) practices (see Figure 2). Response percent for current role were as follows: Clinical
Trial Nurse (40.9%); Infusion Nurse (36.4%); Clinical Nurse Specialist (22.7%) (see Figure 1).
A total of 3 skipped this question and 4 specified an “other” response of nurse manager/educator.
For the 18 nurses who responded “yes” to having administered rituximab with both the standard
infusion and faster infusion schedules, 60% responded that their current role was Clinical Trial
Nurse.
Figure 1
Oncology Nurses’ Roles
What is your current role?
0%
23%

Nurse Practitioner

41%

Clinical Nurse Specialist
Infusion Nurse
Clinical Trial Nurse

36%
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Figure 2
Oncology Nurses’ Practice Setting
Which of the following best describes your practice setting?
35.0%

32.0%

30.0%
25.0%

24.0%
20.0%

20.0%

20.0%

16.0%

15.0%
10.0%
5.0%
0.0%
Academic
Medical Center

Community
Hospital

Physician
Office/Infusion
Center

Outpatient

Inpatient

Innovativeness
Prior conditions that influence the innovativeness of the 25 nurse respondents are presented
in Tables D2 and D3 in the Appendix. To identify nurses who may be early adopters of
innovations, nurses were asked three questions about leadership and three questions regarding
reliance on others (six total questionnaire items). For the innovativeness factor of leadership,
greater than 80% of total respondents identified themselves as informal/formal leaders whose coworkers asked them about new ideas/practices either “often” or “almost always” (see Figure 3)
and who try new idea/practices when research indicates its value. For the innovativeness factor
of reliance on others, 88% are either “seldom” or “sometimes” reluctant to try something new
and 72% either “seldom” or “sometimes” needed encouragement from others before doing
something new (see Figure 4). Conversely, 72% either “often” or “almost always” network with
other nurses outside of their work environment. The innovativeness questions indicate that
oncology nurses surveyed are willing to accept new ideas and change practice when research
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demonstrates its value and see themselves as opinion leaders who may influence the adoption
and dissemination of innovation within their work environments.
Figure 3
Innovativeness: Leadership
I am considered an informal/formal leader in my work environment
4%
12%
never
seldom
sometimes

52%

often

32.0%

almost always

Figure 4
Innovativeness: Reliance on others
I need encouragement from others before doing something new
4%0%
24%
never
seldom

36%

sometimes
often
almost always

36%
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The following discussion is limited to the 18 nurses who responded “yes” to having
administered rituximab with both the standard infusion and faster infusion schedules. Bar graphs
detailing this subset of survey responses are presented in Appendix E: Figures.
Rituximab Faster Infusion: Nursing Experience
Figure E2 shows that one half (50%) of the oncology nurses have treated greater than or
equal to 11 patients with rituximab faster infusion, with the majority (88.9%) rating their overall
experience with rituximab faster infusion as either “positive” or “very positive.”
Rituximab Faster Infusion Impact: Nursing Impact
Figure E3 shows that most oncology nurses indicated that they either “agree somewhat” or
“strongly agree” that rituximab faster infusion did not impact their abilities to monitor patients
for adverse events (94.4%). These same nurses also either “agree somewhat” or “strongly agree”
that Grade 3 and 4 infusion reactions are disruptive to nursing practice (83.3%), and that they
clearly and accurately document infusion reactions in their practice settings (100%).
Rituximab Faster Infusion Impact: Guidelines, Policies and Procedures
Figure E4 shows that all oncology nurse respondents (100%) either “agree somewhat” or
“strongly agree” that their practice settings have specific guidelines in place for the dosage of
acetaminophen, antihistamines, and corticosteroids for the administration of rituximab.
Although most (83.3%) oncology nurses indicated that they used standing orders or protocols to
manage infusion reactions, one-third (33.3%) reported that their practice settings did not track
quality metrics to assess infusion reaction rates. In addition, a high percentage (38.9%) (see
Figure 5) of oncology nurses responded that they do not have specific guidelines in place for
monitoring vital signs for rituximab faster infusion.
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Figure 5
Guidelines, Policies and Procedures
My practice setting has specific guidelines for monitoring vital signs for
rituximab faster infusion

39%
Yes
No

61%

Rituximab Faster Infusion Impact: Resource Utilization
Figure E5 shows that all oncology nurse respondents (100%) either “agree somewhat” or
“agree strongly” that rituximab faster infusion will improve scheduling efficiency for infusion
chair time. For practices that had specific guidelines for monitoring vital signs for rituximab
faster infusion, monitoring frequency was split, with 40% monitoring vital signs before the
infusion and at 15-minute intervals until infusion completion and 60% with guidelines specifying
a 30-minute monitoring interval.
Rituximab Faster Infusion Impact: Patients
Figure E6 shows that all oncology nurses surveyed (100%) either “agree somewhat” or
“agree strongly” that nurses in their practice settings educate patients and their families about
infusion reactions and encourage reporting of infusion reactions to clinicians. All agreed (100%)
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that patients would prefer the administration of rituximab faster infusion, with 83.3% indicating
that they “agree strongly.”
Rituximab Faster Infusion Impact: Safety
Figure E7 shows that although the majority (82.5%) of oncology nurse respondents either
“disagree somewhat” or “disagree strongly” that rituximab faster infusion increases the
likelihood of a patient experiencing an infusion-related reaction compared to a standard infusion
rate, 17.6% were “not sure.” However, all respondents agreed that the administration of
rituximab faster infusion was safe, with 66.7% indicating that they “agree strongly.”
Rituximab Faster Infusion Impact: Overall Impression
Figure E8 shows that 94.5% of oncology nurses had an overall impression that the process
of administering rituximab faster infusion was either “easy” or “very easy,” and all agreed that
they would recommend rituximab faster infusion to patients, with 72.2% indicating that they
“agree strongly” in recommending this to patients.
These new data fill a gap in the existing body of knowledge about nursing perceptions
about the safety of rituximab faster infusion and the impact of this innovation on nursing practice
and resource utilization. Given that the majority of follicular NHL patients in the United States
receive an initial treatment strategy that includes the infusion of rituximab and that the US FDA
has approved rituximab faster infusion administration, oncology nurses need to assess how to
safely implement this change in drug administration into clinical practice. Both the review of
literature and the survey results are crucial to, and inform the content of, an evidenced-based tool
kit to support oncology nurses’ adoption of rituximab faster infusion.
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Section IV: Evaluation Plan
The appraisal of both research and non-research literature found that there is a sufficient
research base to support adopting a 90-minute administration of rituximab at the second infusion
for patients with NHL. This recommendation is based on literature documenting an incidence of
Grade 3 or 4 infusion-related reactions of 1.1% at Cycle 2 and 2.8% during Cycles 2-8, positive
impact on resource utilization, and increased nursing and patient satisfaction (see Appendix A:
Evidence Table). For a conceptual model to implement rituximab faster infusion into nursing
practice, The Iowa Model of Evidence-Based Practice to Promote Quality Care (Titler et al.,
2001) was selected (see Figure E1). In addition, given that the diffusion of innovation is an
identified barrier preventing the adoption and translation of research findings into evidencebased practice, Roger’s Diffusion of Innovations model was selected as the strategy to facilitate
the successful adoption of rituximab faster infusion.
Although the adoption of a 90-minute schedule has been recommended due to both
perceived positive impact on resource utilization (reduction in nursing workload and elimination
of treatment waiting times for rituximab) and projected increased patient satisfaction, there is
still little evidence in the literature that quantifies these positive impacts. Therefore, to support
the translation of the rituximab faster infusion innovation into nursing practice, a tool kit was
created for oncology nurses to conduct their own 30-day pilot assessments of the real-world
impacts of rituximab faster infusion on nursing practice, patient safety, and resource utilization.
The target audience for this tool kit is oncology nurse early adopters who are either self
identified or identified by nursing leadership within a practice setting.
The tool kit is composed of 3 documents:
•

One Page Handout consisting of:
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o Front page: Process to Minimize Medication Administration Error Risk When
Adopting Rituximab Faster Infusion - 5 Rights for Medication Administration
(Table 3)
o Back page: Adoption of Rituximab Faster Infusion - Monitor and Analyze
Structure, Process and Outcome Data (Figure E9)
•

Innovativeness and Overall Impression Assessment Tool (Figure E10)

•

Current version of Rituximab (Rituxan®) Prescribing Information:
http://www.gene.com/gene/products/information/pdf/rituxan-prescribing.pdf.

The 5 rights (5 R’s) for medication administration include 1) right patient, 2) right drug, 3)
right dose, 4) right route, and 5) right time. These 5 R’s were developed for nurses as a
standardized process to minimize risk of error when administering medications. This process has
been critiqued as being inadequate because the process ignores the role of the patient and their
families in patient safety (Macdonald, 2010). Given this criticism and data from the survey of
oncology nurses supporting the role of patients and their families in reporting infusion reactions,
patients were included in the tool kit (see Table 3).
The Innovativeness and Overall Impression Assessment Tool presented in Figure E10 is
designed to identify nurses who may be early adopters and to assess nurses’ overall impression
of rituximab faster infusion (pre and post adoption). These questions may be administered at a
practice setting via SurveyMonkey ™, verbally, or on paper.
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Table 3
Process to Minimize Medication Administration Error Risk When Adopting Rituximab Faster
Infusion - 5 Rights for Medication Administration
BLACK BOX WARNING: FATAL INFUSION REACTIONS, TUMOR
LYSIS SYNDROME (TLS), SEVERE MUCOCUTANEOUS REACTIONS, and
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML). Fatal
infusion reactions within 24 hours of RITUXAN infusion occur; approximately
80% of fatal reactions occurred with first infusion. Monitor patients and
discontinue RITUXAN infusion for severe reactions. See full prescribing
information for complete boxed warnings.
For previously untreated follicular NHL and DLBCL patients.
Right
Patient
Patients who did not experience a Grade 3 or 4 infusion related adverse
event during Cycle 1.

Right
Drug

Patients who have clinically significant cardiovascular disease or who
have a circulating lymphocyte count ≥5000/mm3 before Cycle 2 should
not be administered the 90-minute infusion.
Rituximab (Rituxan) Injection for Intravenous Use
•
•

Right
Dose

Right
Route
Right
Time
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Recommended to pre-medicate before each infusion with
acetaminophen and an antihistamine.
In the RATE trial patients with follicular NHL received rituximab
375 mg/m2 plus CVP chemotherapy and patients with DLBCL
received rituximab 375 mg/m2 plus CHOP chemotherapy.
o All patients received the glucocorticoid component of their
chemotherapy prior to Rituximab (Rituxan) infusion.

The Rituximab (Rituxan) dose for NHL is 375 mg/m2
Initiate at a rate of:
• 20% of the total dose given in the first 30 minutes and the
remaining.
• 80% of the total dose given over the next 60 minutes.
o Total infusion time is 90-minutes.
For infusion reactions, interrupt the infusion or slow the infusion rate.
Continue the infusion at one-half the previous rate upon improvement
of symptoms.
Administer only as an Intravenous Infusion. Do not administer as an
intravenous push or bolus.
If the 90-minute infusion is tolerated in Cycle 2, the same rate can be
used when administering the remainder of the treatment regimen
(through Cycle 6 or 8). Patients should be monitored after each
rituximab infusion according to standard institutional practice.
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To obtain expert opinion evidence that the tool kit is clinically accurate and appropriate to
assist oncology nurses in adopting rituximab faster infusion, an interdisciplinary panel composed
of four members of a US Medical Affairs Medical Team within a large global pharmaceutical
company was identified. Panel members included two Master’s prepared nurses with the role of
Hematology Medical Science Liaison, one PhD prepared Hematology Medical Science Director
responsible for the clinical review of materials provided to health care professionals, and one
PharmD prepared Project Manager responsible for US Medical Team project management
support.
This interdisciplinary panel was sent an email in November 2012 that included a
SurveyMonkey ™ link to images of Figures E9, E10, and Table 3 for review/reference and a 5item questionnaire. The survey included two demographic questions regarding panel member’s
role within the company and their highest level of education completed. The panel was then
asked to evaluate the clinical accuracy and overall usefulness of the tool kit components using a
5-point Likert scale ranging from “agree strongly” to “disagree strongly.” Figure 6 shows that at
least 75% of panel members either “agree somewhat’ or “agree strongly” that the components of
the tool kit were clinical accurate, assist with obtaining practice setting evidence, and inform the
adoption of rituximab faster infusion by oncology nurses. Table 3 received the strongest
agreement (50%) for clinical accuracy, and 100% agreed that the 5 Rights of Medication
Administration tool would assist oncology nurses to safely administer rituximab faster infusion.
After receiving expert panel feedback/comments via an open text field, the tool kit was
modified to highlight the chemotherapy regimens in the RATE trial and include a reference that
the 90-minute infusion was administered in combination with corticosteroid-containing
chemotherapy. The entire panel agreed (100%) that Figure E9 would assist oncology nurses to
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obtain practice setting evidence regarding the impact of rituximab faster infusion on nursing

practice, guidelines, policies and procedures, resource utilization, and patients. The entire panel
agreed that the Innovativeness Instrument and Overall Impression Survey asks questions that
could inform the adoption of rituximab faster infusion by oncology nurses.
Figure 6
Expert Opinion Panel Assessment of Tool Kit

Expert Opinion Assessment of Tool Kit
Q1 and Q2 (Innovativeness Instrument and
Overall Impression Survey) asks questions
that could inform the adoption of rituximab…
Figure 9 would assist oncology nurses to
obtain practice setting evidence regarding
the impact of rituximab faster infusion on…
Figure 9 (Adoption of Rituximab Faster
Infusion) is clinically accurate
Table 3 would assist oncology nurses to
safely administer rituximab faster infusion
Table 3 (5 Rights for Medication
Administration) is clinically accurate
0%

20%

40%

60%

disagree strongly

disagree somewhat

not sure

agree

agree somewhat

agree strongly

80%

100%

Oncology nurse early adopters who use the tool kit to conduct 30-day pilots to assess the
real-world impact of rituximab faster infusion on nursing practice, patient safety, and resource
utilization should consider incorporating the proposed Quality Oncology Practice Initiative
(QOPI®) measures specific to rituximab faster infusion (see Table 4). QOPI is a quality
assessment and improvement program for US-based outpatient hematology-oncology practices
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designed to promote excellence in cancer care by providing practices with quality improvement
tools and measures to improve cancer care (Neuss, Gilmore, & Kadlubek, 2011). QOPI
measures are derived from clinical guidelines or published standards and are adapted from the
National Initiative on Cancer Care Quality (NICCQ), American Society of Clinical Oncology
(ASCO)/ National Comprehensive Cancer Network (NCCN) Quality Measures, and are
consensus-based and clinically relevant. In 2012, there were 97 quality measures, including five
specific to NHL, three of which specific to rituximab. Measures 77 and 77a refer to the
administration of rituximab when CD antigen expression is either negative or undocumented
and the inverse, when CD 20 antigen expression is positive. Measure 78 refers to obtaining a
documented hepatitis B virus infection test, including HBsAg, prior to administration of
rituximab for patients with NHL (Quality Oncology Practice Initiative, 2012).
The tool kit and rituximab faster infusion QOPI proposed measures are resources to assist
with the adoption, safe implementation ,and evaluation of this innovation on both patient
outcomes and nursing practice. Table 4 lists new QOPI measures proposed for rituximab faster
infusion as part of the project’s continuous improvement evaluation plan. Since QOPI measures
are reassessed every six months by the QOPI Steering Group composed of both community and
academic oncologists and nurses, nurse members should propose that results of the RATE study
be reviewed for consideration of new QOPI measures.
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Rituximab Faster Infusion QOPI Proposed Measures
Module Quality
Measure
Indicator
NHL
Safety
Rituximab 90
90-minute
minute infusion administered to follicular NHL
and DLBCL patients who did not experience a Grade 3 or 4
infusion related adverse event during Cycle 1.
NHL

Safety

Rituximab 90
90-minute
minute infusion not administered to follicular
NHL and DLBCL patients who have clinically significant
cardiovascular disease or who have a circulating lymphocyte
count ≥5000/mm3 before Cycle 2.

NHL

Safety

Percentage of Grade 3 and 4 IRRs at Cycle 2 and beyond.
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Section V: Implications for Nursing Practice
Rituximab faster infusion will result in a significant change in the administration of this
medication in the United States. Data describing oncology nurses’ perceptions about alternative
immunochemotherapy administration and its impact on safety, resource utilization, and nursing
practice are lacking in the literature. Oncology nurses may have concerns about infusion-related
reactions related to the new 90-minute administration and will require additional resources to
change how they have been administering rituximab over the last 15 years in clinical practice.
The survey of oncology nurses’ attitudes about innovation and perceptions regarding the
impact of rituximab faster infusion on patient safety, nursing practice, and resource utilization,
combined with a systematic review of the literature, provides the best available evidence
regarding the impact of this innovation on nursing practice. These data informed the
development of an evidenced-based tool kit to assist oncology nurses’ adoption of safe and
appropriate interventions that may benefit patient care. Based on expert panel review, using a
tool that incorporates the 5R’s of medication administration may be an effective strategy to
minimize medication error risk when adopting rituximab faster infusion and support achievement
of positive outcomes for both patients and nursing practice.
Clinical Trial Nurses who had administered rituximab faster infusion represented 60% of
survey responders. This finding was influenced by the use of the RATE Study
Coordinator/Study Nurse email list. These nurses also had high innovativeness scores for the
factors of leadership and reliance on others. This indicates a potential willingness among nurses
in this role to accept new ideas and change practice when research demonstrates its value.
Clinical Trial Nurses may be a key early stakeholder to support the translation of innovation into
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practice, especially for academic and community sites that have clinical research programs as
part of their clinical practice.
Additional research exploring oncology nursing interventions related to patient education,
adverse event monitoring, patient-reported quality of life, and quantifying the economic impact
of new methods of medication administration on nursing resources is needed. These new data
will fill gaps in the existing body of knowledge about evidenced-based practices that impact the
delivery of patient care.
Dissemination Plan
To support putting into practice the evidence regarding rituximab faster infusion a
manuscript detailing findings of the review of the literature and implementation plan for an
evidenced-based tool kit may be submitted to nursing journals with high clinical impact (e.g.,
Journal of Infusion Nursing, Journal of Oncology Nursing). In addition, abstracts may be
submitted to national clinical oncology conferences such as the Oncology Nursing Society and
the American Society of Clinical Oncology annual meetings to disseminate results to oncology
nurses.

Keith Dawson

52

ADOPTION OF INNOVATION

References

Agency for Healthcare Research and Quality. (2001). Reducing and Preventing Adverse
Drug Events To Decrease Hospital Costs. Research in Action, Issue 1 Retrieved
October 4, 2012, 2012, from http://www.ahrq.gov/qual/aderia/aderia.htm
American Association of Colleges of Nursing. (2006). The Essentials of Doctoral Education
for Advanced Nursing Practice. In American Association of Colleges of Nursing (Ed.),
(pp. 1-28). Washington, DC.
American Nurses Association. (2010). Nursing: Scope and standards of practice.
Washington, DC: American Nurses Association,.
American Society of Health-System Pharmacists. (1995). ASHP guidelines on adverse drug
reaction monitoring and reporting. Am J Health-Syst Pharm, 128 52:417–419.
Breslin, S. (2007). Cytokine-release syndrome: overview and nursing implications.
[Review]. Clin J Oncol Nurs, 11(1 Suppl), 37-42. doi: 10.1188/07.CJON.S1.37-42
Carlson, C. (2008). Development and testing of four instruments to assess prior conditions
that influence nurses' adoption of evidence-based pain management practices.
[Evaluation Studies, Review]. J Adv Nurs, 64(6), 632-643. doi: 10.1111/j.13652648.2008.04833.x
Carney, P. H., & Ollom, C. L. (2008). Infusion reactions triggered by monoclonal antibodies
treating solid tumors. [Case Reports, Research Support, Non-U.S. Gov't Review]. J
Infus Nurs, 31(2), 74-83. doi: 10.1097/01.NAN.0000313654.57786.bb

Keith Dawson

ADOPTION OF INNOVATION

53

Chiang, J., Chan, A., Shih, V., Hee, S. W., Tao, M., & Lim, S. T. (2010). A prospective study to
evaluate the feasibility and economic benefits of rapid infusion rituximab at an
Asian cancer center. Int J Hematol, 91(5), 826-830. doi: 10.1007/s12185-010-0583-z
Chung, C. H. (2008). Managing premedications and the risk for reactions to infusional
monoclonal antibody therapy. [Review]. Oncologist, 13(6), 725-732. doi:
10.1634/theoncologist.2008-0012
Clinicaltrials.gov. (2011). A study of rituximab alternative dosing rate in patients with
previously untreated diffuse large b-cell or follicular non-Hodgkin's lymphoma
(RATE): ClinicalTrials.gov Identifier: NCT00719472. , 2011, from
http://clinicaltrials.gov/ct2/show/NCT00719472?term=rituximab+infusion&type=Intr&p
hase= &fund=2&rank=12
ClinicalTrials.gov. (2012). Found 353 studies with search of: Open Studies | Exclude
Unknown | Interventional Studies | NHL, from
http://clinicaltrials.gov/ct2/results?term=&recr=Open&no_unk=Y&rslt=&type=Intr&con
d=NHL&intr=&outc=&spons=&lead=&id=&state1=&cntry1=&state2=&cntry2=&state3
=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e=
Colwell, H. H., Mathias, S. D., Ngo, N. H., Gitlin, M., Lu, Z. J., & Knoop, T. (2007). The impact of
infusion reactions on oncology patients and clinicians in the inpatient and
outpatient practice settings: oncology nurses' perspectives. J Infus Nurs, 30(3), 153160. doi: 10.1097/01.NAN.0000270674.13439.5b
Corey, P., Go, R., & Schaper, A. (2007). A nurse can safely deliver rituximab over 90 minutes
Oncology Nursing Forum, 34(2), 493.

Keith Dawson

ADOPTION OF INNOVATION

54

Coulter, C. (2010). Rapid Infusion of Rituximab Works in Community Setting. Clinical
Oncology News, 5(1).
Dakhil, S., Hermann, R., Chai, A., Hurst, D., Fine, G., & Richards, P. (2011). Final results of a
single arm phase III multicenter, open-label study of rituximab administered by faster
infusion in patients with previously untreated diffuse large B-cell (DLBCL) or follicular
non-Hodgkin’s lymphoma (FL). Paper presented at the 53rd American Society of
Hematology Annual Meeting, San Diego, CA.
de Raad J., van Gool K., Haas M., P, H., Faedo M., G., G., . . . Ward, R. (2010). Nursing takes
time: Workload associated with administering cancer protocols. Clinical Journal of
Oncology Nursing, 14(6), 735-741. doi: 10.1188/10.CJON.735-741
Foley, K. A., Wang, P. F., Barber, B. L., Long, S. R., Bagalman, J. E., Wagner, V., . . . Zhao, Z.
(2010). Clinical and economic impact of infusion reactions in patients with
colorectal cancer treated with cetuximab. Ann Oncol, 21(7), 1455-1461. doi:
10.1093/annonc/mdp535
Fortner, B., & Viale, P. H. (2009). Health economic analysis of the burden of infusion
reactions on patients, caregivers, and providers. [Review]. Oncology (Williston Park),
23(2 Suppl 1), 31-36.
Fortner, B. V., Schwartzberg, L. S., Stepanski, E. J., & Houts, A. C. (2007). Human resource
(HR) implications of IV monoclonal antibody (MoAb) infusion reactions (IR): Interim
data from a time and motion study. . Paper presented at the 2007 Gastrointestinal
Cancers Symposium, Orlando, Florida.
Friedberg, J. W., Taylor, M. D., Cerhan, J. R., Flowers, C. R., Dillon, H., Farber, C. M., . . . Link, B.
K. (2009). Follicular lymphoma in the United States: first report of the national
Keith Dawson

ADOPTION OF INNOVATION

55

LymphoCare study. [Research Support, N.I.H., Extramural, Research Support, NonU.S. Gov't]. J Clin Oncol, 27(8), 1202-1208. doi: 10.1200/JCO.2008.18.1495
Genentech. (2012). Rituxan® (Rituximab) US Package Insert (USPI): Prescribing
information. South San Francisco, CA: Author.
Halloran, K., & Barash, P. G. (2010). Inside the black box: current policies and concerns with
the United States Food and Drug Administration's highest drug safety warning
system. [Review]. Curr Opin Anaesthesiol, 23(3), 423-427.
Huddleston, R., Berkheimer, C., Landis, S., Houck, D., Proctor, A., & Whiteford, J. (2005).
Improving patient outcomes in an ambulatory infusion setting: decreasing infusion
reactions of patients receiving paclitaxel and carboplatin. [Evaluation Studies]. J
Infus Nurs, 28(3), 170-172.
Hughes, R. G., & Blegen, M. A. (2008). Medication Administration Safety. In R. G. Hughes
(Ed.), Patient Safety and Quality: An Evidence-Based Handbook for Nurses. Rockville
(MD).
Institute of Medicine (IOM). (2010). Institute of Medicine (IOM) issues report. The future of
nursing: leading change, advancing health. Prairie Rose, 79(4), 6.
Ireland, A. M., DePalma, J. A., Arneson, L., Stark, L., & Williamson, J. (2004). The Oncology
Nursing Society ambulatory office nurse survey. Oncology Nursing Forum, 31(6),
E147-E156.
Jacobson, J. O., Polovich, M., Gilmore, T. R., Schulmeister, L., Esper, P., Lefebvre, K. B., &
Neuss, M. N. (2012). Revisions to the 2009 american society of clinical
oncology/oncology nursing society chemotherapy administration safety standards:

Keith Dawson

ADOPTION OF INNOVATION

56

expanding the scope to include inpatient settings. J Oncol Pract, 8(1), 2-6. doi:
10.1200/JOP.2011.000339
Kohn, L. T., Corrigan, J., & Donaldson, M. S. (2000). To err is human : building a safer health
system. Washington, D.C.: National Academy Press.
Lang, D. S., Hagger, C., & Pearson, A. (2011). Safety of rapid rituximab infusion in adult
cancer patients: a systematic review. [Review]. Int J Nurs Pract, 17(4), 357-369. doi:
10.1111/j.1440-172X.2011.01950.x
Leape, L. L., Berwick, D. M., & Bates, D. W. (2002). What practices will most improve safety?
Evidence-based medicine meets patient safety. [Editorial, Research Support, NonU.S. Gov't]. JAMA, 288(4), 501-507.
Macdonald, M. (2010). Patient safety: examining the adequacy of the 5 rights of medication
administration. Clin Nurse Spec, 24(4), 196-201. doi:
10.1097/NUR.0b013e3181e3605f
Montez, M. (2012, October 18). [Rituxan RATE Launch-MC Training].
National Cancer Institute. (2012a). Non-Hodgkin Lymphoma Retrieved August 25, 2012,
2012, from http://www.cancer.gov/cancertopics/types/non-hodgkin
National Cancer Institute. (2012b). Non-Hodgkin's Lymphoma Retrieved September 15,
2012, from http://www.cancer.gov/cancertopics/types/non-hodgkin
National Coordinating Council for Medication Error. (2012). What is a Medication Error? ,
from http://www.nccmerp.org/
Neuss, M., Gilmore, T. R., & Kadlubek, P. (2011). Tools for measuring and improving the
quality of oncology care: the Quality Oncology Practice Initiative (QOPI) and the
QOPI certification program. Oncology (Williston Park), 25(10), 880, 883, 886-887.
Keith Dawson

ADOPTION OF INNOVATION

57

Oncology Nursing Society. (2011). 2012–2016 ONS Strategic Plan Retrieved October 29,
2011, 2011, from http://www.ons.org/about/StrategicPlan
Ousley, A. L., Swarz, J. A., Milliken, E. L., & Ellis, S. (2010). Cancer education and effective
dissemination: information access is not enough. J Cancer Educ, 25(2), 196-205. doi:
10.1007/s13187-010-0129-3
Palkhivala, A. (2007). Ninety-minute rituximab infusions can be performed safely in patients
with non-Hodgkins lymphoma. Abstract 2010. April 24-27, 2007. Paper presented at
the Oncology Nursing Society 32nd Annual Congress, Las Vegas, NV.
Pharmaceutical Research and Manufacturers of America. (2012). About PhRMA Retrieved
September 17, 2012, 2012, from http://www.phrma.org/about/about-phrma
Quality Oncology Practice Initiative. (2012). Review Methodology and Measures: Fall 2012
Retrieved November 13, 2012, from
http://qopi.asco.org/Documents/QOPIFall12MeasuresSummary_008.pdf
Rogers, E. M. (2003). Diffusion of innovations (5th ed.). New York: Free Press.
Rummel, M. (2010). Reassessing the standard of care in indolent lymphoma: a clinical
update to improve clinical practice. [Review]. J Natl Compr Canc Netw, 8 Suppl 6, S114; quiz S15.
Schwappach, D. L., Hochreutener, M. A., & Wernli, M. (2010). Oncology nurses' perceptions
about involving patients in the prevention of chemotherapy administration errors.
[Research Support, Non-U.S. Gov't]. Oncol Nurs Forum, 37(2), E84-91. doi:
10.1188/10.ONF.E84-E91
Schwartzberg, L. S., Stepanski, E. J., Fortner, B. V., & Houts, A. C. (2008). Retrospective chart
review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in
Keith Dawson

ADOPTION OF INNOVATION

58

community oncology practices: assessment of clinical consequences. [Research
Support, Non-U.S. Gov't]. Support Care Cancer, 16(4), 393-398. doi:
10.1007/s00520-007-0329-5
Schwartzberg, L. S., Stepanski, E. J., Walker, M. S., Mathias, S., Houts, A. C., & Fortner, B. V.
(2009). Implications of IV monoclonal antibody infusion reaction for the patient,
caregiver, and practice: results of a multicenter study. [Comparative Study,
Multicenter Study, Research Support, Non-U.S. Gov't]. Support Care Cancer, 17(1),
91-98. doi: 10.1007/s00520-008-0474-5
Sehn, L. H., Donaldson, J., Filewich, A., Fitzgerald, C., Gill, K. K., Runzer, N., . . . Connors, J. M.
(2007). Rapid infusion rituximab in combination with corticosteroid-containing
chemotherapy or as maintenance therapy is well tolerated and can safely be
delivered in the community setting. [Clinical Trial]. Blood, 109(10), 4171-4173. doi:
10.1182/blood-2006-11-059469
Swan, J. T., Murillo, J. R., Cox, J. E., Lamoth, B., & Baker, K. R. (2010). Assessment of safety
regarding rapid rituximab infusion. Community Oncology, 7, 458-461.
The Leukemia & Lymphoma Society. (2012). Disease Education and Supprt: Lymphoma
Retrieved September 17, 2012, 2012, from http://www.lls.org/ /diseaseinformation/lymphoma/
Titler, M. G., Kleiber, C., Steelman, V. J., Rakel, B. A., Budreau, G., Everett, L. Q., . . . Goode, C. J.
(2001). The Iowa Model of Evidence-Based Practice to Promote Quality Care. Crit
Care Nurs Clin North Am, 13(4), 497-509.

Keith Dawson

ADOPTION OF INNOVATION

59

United States Department of Health and Human Services. (2010). Common terminology
criteria for adverse events (CTCAE) Version v4.03 Published: June 14, 2010, from
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
United States Department of Health and Human Services. (2011). Goal 1: Transform health
care. Retrieved October 29, 2011, 2011, from
http://www.hhs.gov/secretary/about/goal1.html
United States Food and Drug Administration. (2012). About the FDA: FDA Fundamentals
Retrieved October 12, 2012, 2012, from
http://www.fda.gov/AboutFDA/Transparency/Basics/ucm192695.htm
Vogel, W. H. (2010). Infusion reactions: diagnosis, assessment, and management. [Review].
Clin J Oncol Nurs, 14(2), E10-21. doi: 10.1188/10.CJON.E10-E21
Wagner, A. K., Chan, K. A., Dashevsky, I., Raebel, M. A., Andrade, S. E., Lafata, J. E., . . . Platt, R.
(2006). FDA drug prescribing warnings: is the black box half empty or half full?
[Research Support, U.S. Gov't, P.H.S.]. Pharmacoepidemiol Drug Saf, 15(6), 369-386.
doi: 10.1002/pds.1193
Westbrook, J. I., Rob, M. I., Woods, A., & Parry, D. (2011). Errors in the administration of
intravenous medications in hospital and the role of correct procedures and nurse
experience. [Research Support, Non-U.S. Gov't]. BMJ Qual Saf, 20(12), 1027-1034.
doi: 10.1136/bmjqs-2011-000089
World Health Organization. (2012). ICD-10 Version:2010: Malignant neoplasms, stated or
presumed to be primary, of lymphoid, haematopoietic and related tissue (C81-C96)
Retrieved September 15, 2012, 2012, from
http://apps.who.int/classifications/icd10/browse/2010/en - /C81-C96
Keith Dawson

ADOPTION OF INNOVATION

60

Wulff, K., Cummings, G. G., Marck, P., & Yurtseven, O. (2011). Medication administration
technologies and patient safety: a mixed-method systematic review. [Research
Support, Non-U.S. Gov't Review]. J Adv Nurs, 67(10), 2080-2095. doi:
10.1111/j.1365-2648.2011.05676.x
Zahrani, A., Ibrahim, N., & Eid, A. (2009). Rapid infusion rituximab changing practice for
patient care. [Case Reports, Clinical Trial]. J Oncol Pharm Pract, 15(3), 183-186. doi:
10.1177/1078155208100527
Zetka, E. S. (2012). The essentials of chemotherapy-induced infusion reactions. Clin J Oncol
Nurs, 16(5), 527-529. doi: 10.1188/12.CJON.527-529

Keith Dawson

Running head: ADOPTION OF INNOVATION

61

Appendix A: Evidence Table
What evidence exists regarding the safety of administrating rituximab faster infusion and the impacts of this innovation on nursing
practice and resource utilization?
Study

Method

Sample

Intervention

Outcomes/
Recommendations

Lang et al,
2011

Metaanalysis:
systematic
review
based on the
Joanna
Briggs
Institute
Model of
EvidenceBased
Health Care
Experiment
al, single
arm

559 NHL
patients

Rituximab 90
min Infusion
vs. rate > 120
minutes

12 (2.6%) acute adverse reactions were reported among
559 patients who completed 1799 cycles of rapid
rituximab infusion in nine studies. Grade 1: n=7, Grade
2: n=5, Grade 3/4: n=0

Sehn et al,
2007
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Stren
gth of
Evide
nce
I-V
II

Quali
ty of
Evide
nce
A-C
A

!!

A

Based on best available evidence, a 90 min rapid
rituximab infusion is recommended for NHL patient at
second infusion and the frequency of nursing
monitoring should be readjusted to reduce workforce
waste.

150 NHL
safety
cohort,
>1200
treated
(Canada)

Rituximab 90
min Infusion in
combo with
corticosteroidcontaining
chemo

More than 1,200 patients treated with rapid infusion
rituximab in BC with only one Grade III reaction. The
authors recommend the adoption of a 90-minute
schedule due to a positive impact on resource utilization
(reduction in nursing workload and elimination of
treatment waiting times for rituximab) and increased
patient satisfaction.
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Study

Method

Sample

Intervention

Outcomes/
Recommendations

Chaing et
al, 2010

Experiment
al, single
arm

79 NHL
patients
(Single
centerSingapore)

Patient education regarding infusion-related reactions
with rituximab is crucial to aid in the identification of
patients who are not suitable for the rapid infusion.
Patients who are prone to nausea and vomiting should
also be considered for omission from the rapid schedule
pending further investigation.

Corey et al,
2007

Experiment
al, single
arm

Coulter et
al, 2010

Experiment
al, single
arm

33 NHL
patients
(Single
center- US
community
cancer
center)
16 NHL
patients (3
US
communitybased
outpatient
infusion
clinics)

Rituximab 90
min Infusion
(single agent
rituximab
without
corticosteroid
therapy)
Rituximab 90
min Infusion in
combo with
corticosteroidcontaining
chemo
Rituximab 90
min Infusion
(premedications
not
standardized)
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Quali
ty of
Evide
nce
A-C
A

Rituximab 90-minute was safe and improved resource
utilization and patient satisfaction as evidenced by
providing patients with more flexibility in treatment
scheduling, more time away from the facility and
increasing access in the chemotherapy suite.

II

B

If medical oncologists adopt rituximab faster infusion as
standard practice, an easier monitoring schedule than
measuring blood pressure, heart rate and respiratory rate
before the infusion and at 15, 30, 60 and 90 minutes to
monitor respiratory or cardiac symptoms should be
employed to free up nursing time and resources.

II

B
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Study

Method

Sample

Intervention

Outcomes/
Recommendations

Swan et al,
2010

Experiment
al, single
arm

13 NHL
patients
(Single
center- US
Hospital
outpatient
and
inpatient
units)

Rituximab 90
min Infusion
(premedication
with
acetaminophen
and
diphenhydrami
ne,
corticosteroids
not described)

One Grade 3 reaction of prolonged hypotension,
tachycardia, and fever.

Zahrani et
al, 2007
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Experiment
al, single
arm

21 NHL
patients
majority of
patients
were treated
with RChemo
regimens
(Hospital Saudi
Arabia)

Stren
gth of
Evide
nce
I-V
II

Quali
ty of
Evide
nce
A-C
A

Adopting a rapid infusion schedule would benefit
patients and the institution by reducing clinic chair time
for each dose by 1.5–2 hours, compared with standard
infusion times.

Adoption of a rapid administration protocol will succeed
only if supported by the nursing staff. Strong nursing
leadership and educational in-services highlighting
safety data will help gain support and comfort required
for nursing staff to treat patients with rituximab faster
infusion and decreasing resource utilization of infusion
clinic time by ensuring that premedication is given and
that the rituximab faster infusion is started in a timely
manner.
Rituximab 90
No Grade 3/4 infusion-related adverse events observed
II
min Infusion in This shortened infusion schedule has resulted in a
combo with
substantial reduction in resource utilization.
corticosteroidcontaining
Preliminary data may be used to develop alternative
chemo
guidelines for administration of rituximab to achieve
resource utilization benefits.
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Study

Method

Sample

Intervention

Outcomes/
Recommendations

Schwartzbe
rg et al,
2008

Nonexperimenta
l- crosssectional
chart review

76 patients
identified
with a
severe IRR:
47
rituximab
cases
(19 US
community
oncology
centers)

N/A

21% of rituximab severe IRR cases received
corticosteroids before MoAb treatment.

Dakhil et
al, 2011

Quasi451 FL and
experimenta DLBCL
l- single
patients
arm phase
III
multicenter
open label
study

Quali
ty of
Evide
nce
A-C
A

II

A

Nearly half of the patients who received rituximab and
experienced a severe IRR were receiving rituximab
alone. 17% of rituximab Grade 3 IRRs resulted in
permanent discontinuation. For those not discontinuing,
dose delays and infusion rate reductions were common,
but actual dose reduction was rare.
Well-rehearsed plans and procedures for handling these
events can help staff to reassure other patients in general
and especially those who may be receiving similar
therapies.
Rituximab 90
The incidence of Grade 3/4 IRRs at Cycle 2 was low
min Infusion in (1.1%) and the rate of IRRs decreased with subsequent
combo with
administrations
corticosteroidcontaining
Only 10 patients (2.8%) experienced Grade 3/4 IRRs
chemo
during Cycles 2–8
There were no fatal IRRs or fatal AEs on Days 1–2 at
any cycle in this study, and there were no unexpected
events or acute fatal events associated with the faster
infusion schedule.
Results from this study confirm that the 90-minute
infusion schedule for rituximab is safe and feasible in
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Method

Sample

65
Intervention

Outcomes/
Recommendations

Stren
gth of
Evide
nce
I-V

Quali
ty of
Evide
nce
A-C

III

A

NHL patients who tolerate their first infusion
administered at the standard rate and who do not have
significant cardiovascular disease or high circulating
lymphocytes.
de Raad et
al, 2010

Qualitativediscussion
group
sessions

36 nurses
(6
chemothera
py centers
in New
South
Wales,
Australia)

A major
limitation of
this study is
that it is not
specific to
rituximab
faster infusion

Four task types and time averages associated with
administering chemotherapy:
1. patient education - 48 minutes during the first visit
and 18.5 minutes thereafter
2. patient assessment - 20.3 minutes,
3. administration - 23 minutes,
4. patient communication - 24.2 minutes
Each patient received 3.3 hours of staff time (1.7 hours
of direct contact time and 1.6 hours of noncontact time).
These data will allow healthcare decision makers and
evaluators to predict the amount of nursing time
required to administer chemotherapy based on the
characteristics of a wide range of chemotherapy
protocols.
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Study

Method

Sample

Intervention

Outcomes/
Recommendations

Schwartzbe
rg et al,
2009

QualitativeA
prospective
multicenter
study
involving
time and
motion and
activity
sampling
methods

Of 161
enrolled, 90
patients
received
rituximab
(27 US
community
oncology
sites)

A major
limitation of
this study is
that it is not
specific to
rituximab
faster infusion

IRRs following rituximab administration are common
and are associated with measurably increased costs of
care Among 161 patients enrolled, 39% of 90 patients
on rituximab experienced IRRs.

Keith Dawson

A statistically significant finding was mean human
resource costs ranging from $54 to $118 for no IRR to
mild/moderate IRR: F (2, 6.448)=5.858, p=.035
(mild/moderate > no IRR).
The frequency of IRRs suggests the importance of
identifying clinical guidelines for intervention and
management. The methods used in this study could be
employed for any direct comparison of chemotherapy
regimens that purports to examine treatment cost as an
outcome.
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Study

Method

Sample

Intervention

Outcomes/
Recommendations

Colwell et
al, 2007

QualitativeSurvey

202 nurses
(99%
women)

A major
limitation of
this study is
that it is not
specific to
rituximab
faster infusion

96% of nurses reported that Grade 3 or 4 infusion
reactions were “very” or “extremely” disruptive for
patients, and most nurses indicated that Grade 3 or 4
infusion reactions were disruptive to the nurses (80%).

Schwappac
h et al,
2010

QualitativeSurvey

11 actively
practicing
US
oncology
nurses

A major
limitation of
this study is
that it is not
specific to
rituximab
faster infusion

Quali
ty of
Evide
nce
A-C

III

A

95% of nurses agreed with the statement, “Infusion
reactions can result in lost time and increased patient
anxiety”), with a greater proportion of outpatient nurses
than inpatient nurses agreeing or strongly agreeing with
this statement (98% versus 90%, respectively; P ≤ .05).
Infusion reactions associated with parenteral MoAb
treatments and chemotherapy are disruptive and
emotionally challenging for patients receiving the
treatment and the nurses and staff at the institution or
practice treating them. The results suggest that further
awareness of infusion reaction management and
education of patients and clinicians are needed.
Oncology nurses perceive patient education in safety as
a core element of their professional role and are
receptive to advancing their expertise in this area.
Engaging patients was described as a challenge and
nurses acknowledged the diverse needs of patients and
deliberately used different strategies to involve patients
in safety.
Oncology nurses should include patient involvement in
error prevention given the reported positive experiences.
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Method

Breslin, S,
2007

Expert
N/A
OpinionPrinciples
related to
cytokinerelease
syndrome in
patients
receiving
MOABs
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Sample

68
Intervention

Outcomes/
Recommendations

N/A

1. Prior to administering any MoAb, nurses should be
familiar with its toxicity profile, including the
potential for acute and delayed infusion-related side
effects.
2. The need for specific pre-medications should be
assessed.
- For patients with circulating lymphocyte counts of
25,000/mm3 or higher, the addition of
corticosteroids and histamine-2 receptor antagonists
to the usual pre-medications is recommended.
- Hospitalization of such patients for inpatient
administration of medication and close monitoring
should be strongly considered
3. MoAbs always should be administered piggy-back
into the distal port of a main IV line and never
should be given as an IV bolus.
4. An infusion pump always should be used for
administration. The first infusion should be
administered slowly. Subsequent infusions may be
given more rapidly as tolerated and per package
instructions.
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Study

Method

Sample

Intervention

Outcomes/
Recommendations

Chung, C,
2008

Literature
ReviewManaging
Premedications
and risk of
IRRs with
MoAbs

N/A

N/A

Improving risk assessment for infusion reactions has
become a compelling medical need.

Vogel, W,
2010

Expert
N/A
OpinionInfusion
Reactions,
Diagnosis,
Assessment
&
Managemen
t

Quali
ty of
Evide
nce
A-C
A

Patients with high circulating malignant cell counts are
at risk for severe infusion reactions to rituximab. Premedications are considered standard procedure for
minimizing the risk for IRRs.

N/A

Because most infusion reactions with monoclonal
antibodies occur after the first or second infusion, the
value of premedication on subsequent infusions may
decrease.
Safety assessments from six studies of rituximab used as V
a single agent in previously treated patients with
indolent non-Hodgkin lymphoma gave an incidence of
infusion-related reaction in 77% (7% Grades 3–4) of
patients during the first infusion, 30%
(2% Grades 3–4) during the fourth infusion, and 14%
(no Grade 3–4 events) during the eighth infusion.
Rituximab is associated with infusion reactions that are
caused primarily by cytokine release rather than true
allergic reactions.
Prompt and accurate documentation of the infusion
event including accurate grading of the event will enable
the prescribing clinician to decide whether re-challenge
is feasible and safe.
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Method

Sample
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Intervention

Outcomes/
Recommendations

Stren
gth of
Evide
nce
I-V

Quali
ty of
Evide
nce
A-C

V

B

Re-challenge may include the re-administration of
antihistamines and corticosteroids, followed by
administration of the agent at a reduced rate.
Palkhivala,
A, 2007

Expert
Opinion-90
minute
rituximab
infusion

N/A

N/A

“Patients were pleased with shortened infusion times,
more time away from [the] facility, [and] more control
and flexibility in [their] treatment scheduling."
Rituximab faster infusion. “… will make a huge
difference to practice to free up those [treatment]
chairs."
According to Rogers, before rituximab faster infusion
becomes standard practice in the United States more
data is needed because of the large impact that faster
infusion this will have on nursing practice and resource
utilization.
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Study

Method

Sample

Intervention

Outcomes/
Recommendations

Fortner &
Viale, 2007

Review of
Literatureeconomic
analysis of
infusion
reactions

N/A

N/A

Time and motion studies are suggested as a model for
community oncology centers to assess the tasks
involved and the associated costs in treating IRRs
caused by therapies such as rituximab and help to
evaluate intervention strategies for IRRs that may have a
significant impact on centers with limited staff
resources.
The incidence of an IRR resulted in increased MoAb
infusion times and staff time, leading to increased
human resource costs. Compared to patients not
experiencing IRRs, statistically significant increases in
staff time during infusion were observed in patients
experiencing IRRs. Prevention, including patient
education about IRR risks, and proper management of
IRRs may minimize these expenses for patients and
families.

Keith Dawson

Stren
gth of
Evide
nce
I-V
V

Quali
ty of
Evide
nce
A-C
A

Running head: ADOPTION OF INNOVATION

Appendix B: Research and Non-Research Appraisal Forms

Newhouse, R., Dearholt, S., Poe, S., Pugh, L., & White, K. (2007). Johns Hopkins nursing
evidence-based practice model and guidelines.
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RESEARCH- Appraisal

Evidence Level: IIA
Article Title: Safety of rapid rituximab infusion in adult cancer patients: A systematic review
Author(s)
Lang DSP, Hagger C, Pearson A.
Date: 2011
Journal:
International Journal of Nursing Practice
Setting:
NHL patients in 90 min regimen
Sample Size: 559 NHL patients
Experimental
MetaQuasiNonMeta-synthesis
analysis
experimental experimental Qualitative
Yes
No
Does this study apply to NHL patients?
If the answer is No, STOP here (unless there are similar characteristics)
Strength of Study Design
Yes
No
• Was the sample size adequate and appropriate?
Yes
No
• Were study participants randomized?
Yes
No
• Was there an intervention? Rituximab infused over 30 min
for 20% of the total dose at the beginning and the remaining
80% was infused over 60 min.
Yes
No
• Was there a control group? The comparator group was any
rituximab infusion rate > 120 min or without a comparison
group.
Yes N/A
No N/A
• If there was more than one group, were groups equally
treated, except for the intervention?
Yes
No
• Was there adequate description of the data collection
methods?
Study Results
Yes
No
• Were results clearly presented?
Yes
No
• Was an interpretation/analysis provided?
Study Conclusions
Yes
No
• Were conclusion based on clearly presented results?
Yes
No
• Were study limitations identified and discussed?
Pertinent Study Findings and Recommendations:
Safety
This systematic review was based on the Joanna Briggs Institute Model of Evidence-Based Health
Care to critically appraise, synthesize and present the best available evidence to inform clinical
practice. A meta-analysis of NHL patients in 90 min regimen using a random effects model
(DerSimonian–Larid) showed a pooled proportion of 0.026 (95% CI, 0.01, 0.048), translated to 2.6%
of acute adverse reactions among nine studies of 559 NHL patients. The studies were homogenous
as non-combinability test showed P = 0.0955 and I2 = 40.8% (95% CI, 0%, 71.3%). No publication
bias was detected in Harbord bias test, P = 0.30
A total of 12 acute adverse reactions were reported among 559 patients who completed 1799 cycles of
rapid rituximab infusion in nine studies, which consisted of NHL patient in 90 min regimen. Grades
for acute adverse reactions were reported as follows: Grade 1: n=7, Grade 2: n=5, Grade 3/4: n=0
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The most common reported acute adverse reactions were nausea and vomiting followed by rash; chills
and rigors; back pain, abdominal pain; sore throat; and hypotension. All these studies used
antipyretics, namely acetaminophen/paracetamol, ranging from 375 to 1000 mg either in the form of
tablet(s) or by injection.
The most common antihistamine was either oral or parenteral diphenhydramine 25–50 mg. The
common choice of corticosteroids was parenteral hydrocortisone 100 mg, prednisolone 100 mg and
methylprednisolone
Recommendations
Based on best available evidence, a 90 min rapid rituximab infusion is recommended for NHL patient
at second infusion and the frequency of nursing monitoring should be readjusted to reduce workforce
waste.
Will the results answer the practice question?

Strength of
Level I
Evidence
(Strong)
Quality of Evidence (check one)
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Evidence Rating
Level
Level
II
III
High
(A)

Yes

No

Level IV

Level V.

Good
(B)

Low/Major flaw
(C)
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RESEARCH- Appraisal

Evidence Level: IIA
Article Title: Rapid infusion rituximab in combination with corticosteroid-containing
chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the
community setting
Author(s)

Laurie H. Sehn, Jane Donaldson, Allison Filewich,
Date: 2007
Catherine Fitzgerald, Karamjit K. Gill, Nancy Runzer,
Barb Searle, Sheila Souliere, John J. Spinelli, Judy
Sutherland, and Joseph M. Connors
Journal:
Blood. 2007;109: 4171-4173
Setting:
NHL patients planned for treatment with
Sample Size: 150 patients initial
rituximab in combination with
safety cohort, and more than rapid
corticosteroid-containing chemotherapy at rituximab infusion in > 1200
the BC Cancer Agency
patients in combination with
corticosteroid-containing
chemotherapy
Experimental
MetaQuasiNonMeta-synthesis
analysis
experimental experimental Qualitative
Yes
No
Does this study apply to NHL patients?
If the answer is No, STOP here (unless there are similar characteristics)
Strength of Study Design
Yes
No
• Was the sample size adequate and appropriate?
Yes
No
• Were study participants randomized?
Yes
No
• Was there an intervention? Cycle 1 was unaltered and
delivered according to the product monograph. All further
cycles were administered the same day as chemotherapy over
a total infusion time of 90 minutes (20% of the dose in the
first 30 minutes and the remaining 80% over 60 minutes;
total dose delivered in 250 mL). Patients were encouraged to
take their daily corticosteroid dose according to their
chemotherapy protocol prior to receiving rituximab.
Yes
No
• Was there a control group?
Yes N/A
No N/A
• If there was more than one group, were groups equally
treated, except for the intervention?
Yes
No
• Was there adequate description of the data collection
methods?
Study Results
Yes
No
• Were results clearly presented?
Yes
No
• Was an interpretation/analysis provided?
Study Conclusions
Yes
No
• Were conclusion based on clearly presented results?
Yes
No
• Were study limitations identified and discussed?
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Pertinent Study Findings and Recommendations:
Safety
With initial safety cohort, the rapid infusion rituximab schedule was extremely well tolerated with no
Grade 3 or 4 infusion reactions observed. The rate of Grade 3 or 4 toxicity was 0% (95% CI, 0%0.019%), which is not higher than the expected rate with standard administration.
• 10 patients who had experienced an adverse reaction with their first cycle (administered at the
standard rate) subsequently tolerated rapid infusion without event.
• 8 patients who did not receive any corticosteroids because of a contraindication also tolerated
the rapid infusion without event.
• 0 patients had an elevated circulating lymphocyte count at the time of rapid infusion
rituximab; thus, the safety of rapid infusion of rituximab in this setting remains unknown.
More than 1,200 patients treated with rapid infusion rituximab in BC with only one Grade III
reaction.
Resource Utilization
• Rituximab administration times have been cut in half or less with a concomitant reduction in
nursing workload.
Patient Satisfaction
• Most patients can be conveniently treated with rituximab in a shorter time interval and on the
same day as their chemotherapy. As a consequence, patient satisfaction has improved, and
treatment waiting times for rituximab have been eliminated.
Recommendations
The authors recommend the adoption of a 90-minute schedule due to a positive impact on resource
utilization (reduction in nursing workload and elimination of treatment waiting times for rituximab)
and increased patient satisfaction.
Will the results answer the practice question?
Yes
No

Strength of
Level I
Evidence
(Strong)
Quality of Evidence (check one)
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Evidence Rating
Level
Level
II
III
High
(A)

Level IV

Level V

Good
(B)

Low/Major flaw
(C)
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Evidence Level: IIA
Article Title: A prospective study to evaluate the feasibility and economic benefits of rapid
infusion rituximab at an Asian cancer center
Author(s)
Joen Chiang, Alexandre Chan, Vivianne Shih, Siew Wan Date: 2010
Hee, Miriam Tao, Soon Thye Lim
Journal:
Int J Hematol 91:826–830
Setting:
This was a prospective, single institution,
Sample Size: 79
open label single arm study conducted on
non Hodgkin’s lymphoma patients who
were to receive rituximab at NCCS
(Singapore)
Experimental
MetaQuasiNonMeta-synthesis
analysis
experimental experimental Qualitative
Yes
No
Does this study apply to NHL patients?
If the answer is No, STOP here (unless there are similar characteristics)
Strength of Study Design
Yes
No
• Was the sample size adequate and appropriate?
Yes
No
• Were study participants randomized?
Yes
No
• Was there an intervention? 90 min infusion given without
corticosteroid therapy
Yes
No
• Was there a control group?
Yes
No
• If there was more than one group, were groups equally
treated, except for the intervention?
Yes
No
• Was there adequate description of the data collection
methods?
Study Results
Yes
No
• Were results clearly presented?
Yes
No
• Was an interpretation/analysis provided?
Study Conclusions
Yes
No
• Were conclusion based on clearly presented results?
Yes
No
• Were study limitations identified and discussed?
Pertinent Study Findings and Recommendations:
The rapid infusion of rituximab over 90 min was well tolerated by patients when administered as the
second and subsequent infusions in the course of therapy. The shortened infusion schedule helped to
reduce resource utilization as well as brought time and cost savings to the patient. Patient education
regarding infusion-related reactions with rituximab is crucial to aid in the identification of patients
who are not suitable for the rapid infusion. Patients who are prone to nausea and vomiting should also
be considered for omission from the rapid schedule pending further investigation.
Safety
A total of 79 patients were recruited with a total of 269 infusions administered. The rapid infusion of
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rituximab was well tolerated without any Grade 3/4 infusion-related adverse events observed. In this
study, three patients experienced post-infusion nausea and vomiting - not commonly listed as Grade 3
or 4 adverse reactions (1% for NHL patients).
Resource Utilization
Rituximab rapid infusion resulted in both time and costs savings in resource utilization savings as
measured by reduced facility charges and total amount of chair time saved for patients and the center.
Recommendations
Patient education regarding infusion-related reactions with rituximab is crucial to aid in the
identification of patients who are not suitable for the rapid infusion. Patients who are prone to nausea
and vomiting should also be considered for omission from the rapid schedule pending further
investigation.
Will the results answer the practice question?

Strength of
Level I
Evidence
(Strong)
Quality of Evidence (check one)
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Evidence Rating
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III
High
(A)

Yes

(B)

No

Level IV

Level V

Good

Low/Major flaw
(C)
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Evidence Level: IIB
Article Title: A NURSE CAN SAFELY DELIVER RITUXIMAB OVER 90 MINUTES
Author(s)

Peggy Corey, RN, BSN, OCN®, Ronald Go, MD, and
Date: 2007
Ana Schaper, RN, PhD
Journal:
ONCOLOGY NURSING FORUM – VOL 34, NO 2, 2007
Setting:
Community-based cancer center
Sample Size: 33
Experimental
MetaQuasiNonMeta-synthesis
analysis
experimental experimental Qualitative
Yes
No
Does this study apply to NHL patients?
If the answer is No, STOP here (unless there are similar characteristics)
Strength of Study Design
Yes
No
• Was the sample size adequate and appropriate?
Yes
No
• Were study participants randomized?
Yes
No
• Was there an intervention?
Yes
No
• Was there a control group?
Yes
N/A
No N/A
• If there was more than one group, were groups equally
treated, except for the intervention?
Yes
No
• Was there adequate description of the data collection
methods?
Study Results
Yes
No
• Were results clearly presented?
Yes
No
• Was an interpretation/analysis provided?
Study Conclusions
Yes
No
• Were conclusion based on clearly presented results?
Yes
No
• Were study limitations identified and discussed?
Pertinent Study Findings and Recommendations:
Safety
Patients, with NHL, were enrolled in this modified treatment program if they had received rituximab
according to product monograph within the last 4 months, no prior Grade 3 or 4 infusion related
toxicities, no contra-indication to fluid infusion of 200 ml/hr and an absolute lymphocyte count of
<10,000. Patients were pre-medicated with acetaminophen and diphenhydramine.
Thirty-three patients were treated for total of 88 infusions (median 3). No adverse events were
observed for the 90-minute rituximab infusions. Rituximab infused over 90-minute was safe in the
treatment of NHL and well tolerated in this community cohort.
Patient Satisfaction and Resource Utilization
The reduced infusion time allowed patients more control and flexibility in treatment scheduling, and
more time away from the facility. In addition, shorter infusion times improved access in the
chemotherapy suite.
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Recommendations
The rituximab 90-minute was safe and improved resource utilization and patient satisfaction as
evidenced by providing patients with more flexibility in treatment scheduling, more time away from
the facility and increasing access in the chemotherapy suite.
Will the results answer the practice question?
Yes
No
Evidence Rating
Strength of
Level I
Level
Level
Level IV
Level V
Evidence
(Strong)
II
III
Quality of Evidence (check one)
High
Good
Low/Major flaw
(A)
(B)
(C)
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Evidence Level: IIB
Article Title: Rapid Infusion of Rituximab Works in Community Setting
Author(s)
Chad Coulter, PharmD
Date: 2010
Journal:
Clinical Oncology News ISSUE: JANUARY 2010 | VOLUME: 05:01
Setting:

3 community-based outpatient infusion
Sample Size: 16
clinics
Experimental
MetaQuasiNonMeta-synthesis
analysis
experimental experimental Qualitative
Yes
No
Does this study apply to NHL patients?
If the answer is No, STOP here (unless there are similar characteristics)
Strength of Study Design
Yes
No
• Was the sample size adequate and appropriate?
Yes
No
• Were study participants randomized?
Yes
No
• Was there an intervention?
Yes
No
• Was there a control group?
Yes
N/A
No N/A
• If there was more than one group, were groups equally
treated, except for the intervention?
Yes
No
• Was there adequate description of the data collection
methods?
Study Results
Yes
No
• Were results clearly presented?
Yes
No
• Was an interpretation/analysis provided?
Study Conclusions
Yes
No
• Were conclusion based on clearly presented results?
Yes
No
• Were study limitations identified and discussed?
Pertinent Study Findings and Recommendations:
Safety
Sixteen patients were enrolled and treated with a total of 51 rapid rituximab infusions. The median
number of infusions each patient received was three (range, one to seven). Most of the patients were
younger than 60 and male. Three patients experienced minor adverse reactions which were expected
with rituximab administration.
Premedications were not standardized and could vary per facility protocol. We used a strict safety
monitoring algorithm, measuring blood pressure, heart rate and respiratory rate before the infusion
and at 15, 30, 60 and 90 minutes to monitor respiratory or cardiac symptoms. We also monitored
temperature prior to the infusion
and questioned patients about adverse reactions throughout the infusion and at each visit.
Resource Utilization
The total infusion time saved compared with standard infusion rates was 2,925 minutes (49 hours; 57
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minutes per infusion). Nursing staff, however, did feel that the intense monitoring schedule in this
trial required equal attention to that of the standard infusion. If medical oncologists at these practice
sites adopted this regimen as
standard practice, an easier monitoring schedule should be employed to free up nursing time and
resources.
Patient and Nursing Satisfaction
Patient and nursing satisfaction, assessed through surveys, was extremely high in all but one statement
Recommendations
If medical oncologists adopt rituximab faster infusion as standard practice, an easier monitoring
schedule than measuring blood pressure, heart rate and respiratory rate before the infusion and at 15,
30, 60 and 90 minutes to monitor respiratory or cardiac symptoms should be employed to free up
nursing time and resources.
Will the results answer the practice question?
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Evidence Level: IIA
Article Title: Assessment of safety regarding rapid rituximab infusion
Author(s)
Joshua T. Swan, PharmD, Jose R. Murillo, Jr., PharmD,
Date: 2010
BCOP, James E. Cox, PharmD, Beverley Lamoth, RN,
MSN, OCN, and Kelty R. Baker, MD
Journal:
COMMUNITY ONCOLOGY, Volume 7/Number 10
Setting:
The Methodist Hospital outpatient and
Sample Size: 13
inpatient oncology units.
Experimental
MetaQuasiNonMeta-synthesis
analysis
experimental experimental Qualitative
Yes
No
Does this study apply to NHL patients?
If the answer is No, STOP here (unless there are similar characteristics)
Strength of Study Design
Yes
No
• Was the sample size adequate and appropriate?
Yes
No
• Were study participants randomized?
Yes
No
• Was there an intervention?
Yes
No
• Was there a control group?
Yes N/A
No N/A
• If there was more than one group, were groups equally
treated, except for the intervention?
Yes
No
• Was there adequate description of the data collection
methods?
Study Results
Yes
No
• Were results clearly presented?
Yes
No
• Was an interpretation/analysis provided?
Study Conclusions
Yes
No
• Were conclusion based on clearly presented results?
Yes
No
• Were study limitations identified and discussed?
Pertinent Study Findings and Recommendations:
Safety
Thirteen patients were enrolled in this study for a total of 32 rapid rituximab infusions, all of which
were administered in an outpatient setting. The rapid rituximab infusions were well tolerated by 12 of
the 13 patients in 31 of 32 infusions. There was one Grade 3 reaction of prolonged hypotension,
tachycardia, and fever, which resolved within 24 hours. No other symptomatic infusion reactions
occurred. These results support previously reported data affirming the safety and tolerability of a
rapid, 90-minute infusion for non-initial doses of rituximab in patients with CD20-positive B-cell
malignancy.
Resource Utilization
Adopting a rapid infusion schedule would benefit patients and the institution by reducing clinic chair
time for each dose by 1.5–2 hours, compared with standard infusion times.
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Recommendations
Adoption of a rapid administration protocol will succeed only if supported by the nursing staff. Strong
nursing leadership and educational in-services highlighting safety data will help gain support and
comfort required for nursing staff to treat patients with rituximab faster infusion and decreasing
resource utilization of infusion clinic time by ensuring that premedication is given and that the
rituximab faster infusion is started in a timely manner
Will the results answer the practice question?
Evidence Rating
Strength of
Level I
Level
Level
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II
III
Quality of Evidence (check one)
High
(A)
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Evidence Level: IIB
Article Title: CASE REPORT: Rapid Infusion Rituximab Changing Practice for Patient Care
Author(s)

Ali Al Zahrani, MBBS FRCR, Nagwa Ibrahim, Pharm D, Date: 2007
Ahmed Al Eid, PhD
Journal:
J Oncol Pharm Practice (2009) 15: 183–186.
Setting:
Department of Adult Oncology in Riyadh
Sample Size: 21
Military Hospital in Saudi Arabia
Experimental
MetaQuasiNonMeta-synthesis
analysis
experimental experimental Qualitative
Yes
No
Does this study apply to NHL patients?
If the answer is No, STOP here (unless there are similar characteristics)
Strength of Study Design
Yes
No
• Was the sample size adequate and appropriate?
Yes
No
• Were study participants randomized?
Yes
No
• Was there an intervention?
Yes
No
• Was there a control group?
Yes N/A
No N/A
• If there was more than one group, were groups equally
treated, except for the intervention?
Yes
No
• Was there adequate description of the data collection
methods?
Study Results
Yes
No
• Were results clearly presented?
Yes
No
• Was an interpretation/analysis provided?
Study Conclusions
Yes
No
• Were conclusion based on clearly presented results?
Yes
No
• Were study limitations identified and discussed?
Pertinent Study Findings and Recommendations:
Safety
21 patients with non-Hodgkin’s lymphoma were treated with rituximab-based chemotherapy. A total
of 126 infusions were administered with average of 6 infusions per patient. The majority of patients
were treated with CHOP–Rituximab or CHOP-like regimen. The 90-min Rituximab infusion schedule
was well tolerated with no Grade 3/4 infusion related adverse events observed when administered as
the second and subsequent infusions in the course of therapy.
Resource Utilization (Discussion- no data provided)
The disadvantages of long infusion times for rituximab include prolonged stays in the Chemotherapy
Day Unit for treatment, which is inconvenient for patients, and there is additional workload for nurses.
This shortened infusion schedule has resulted in a substantial reduction in resource utilization.
Recommendations
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Preliminary data may be used to develop alternative guidelines for administration of rituximab to
achieve resource utilization benefits.
Will the results answer the practice question?
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Evidence Level: IIIA
Article Title: Retrospective chart review of severe infusion reactions with rituximab, cetuximab,
and bevacizumab in community oncology practices: assessment of clinical consequences
Author(s)
Lee S. Schwartzberg & Edward J. Stepanski & Barry V.
Date: 2008
Fortner & Arthur C. Hout
Journal:
Support Care Cancer (2008) 16:393–398
Setting:
19 community oncology centers affiliated
Sample Size: 76 patients
with Accelerated Community Oncology
identified with a severe IR: 47
Research Network (ACORN), based in
cases associated with rituximab
Memphis, TN
Experimental
MetaQuasiMeta-synthesis
analysis
experimental Nonexperim Qualitative
ental
Yes
No
Does this study apply to NHL patients?
If the answer is No, STOP here (unless there are similar characteristics)
Strength of Study Design
Yes
No
• Was the sample size adequate and appropriate?
Yes
No
• Were study participants randomized?
Yes
No
• Was there an intervention?
Yes
No
• Was there a control group?
Yes N/A
No N/A
• If there was more than one group, were groups equally
treated, except for the intervention?
Yes
No
• Was there adequate description of the data collection
methods?
Study Results
Yes
No
• Were results clearly presented?
Yes
No
• Was an interpretation/analysis provided?
Study Conclusions
Yes
No
• Were conclusion based on clearly presented results?
Yes
No
• Were study limitations identified and discussed?
Pertinent Study Findings and Recommendations:
Safety
• 47 cases associated with rituximab, All patients treated with rituximab had a hematologic
malignancy
• 21% in the rituximab group received corticosteroids before MoAb treatment
• Nearly half of the patients who received rituximab and experienced a severe IR were receiving
rituximab alone
• 17% of rituximab Grade 3 IRs resulted in permanent discontinuation. For those not
discontinuing, dose delays and infusion rate reductions were common, but actual dose
reduction was rare
Resource Utilization (Discussion- no data provided)
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Severe IRs have substantial cascading effects in clinical resources and workflow. A severe IR requires
chemotherapy nurses, technicians, and doctors to make severe adjustments to maintain care of already
scheduled patients.
Recommendations
Having well-rehearsed plans and procedures for handling these events can help staff to reassure other
patients in general and especially those who may be receiving similar therapies
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Evidence Level: IIA
Article Title: Final results of a single arm phase III multicenter, open-label study of rituximab
administered by faster infusion in patients with previously untreated diffuse large B-cell
(DLBCL) or follicular non-Hodgkin’s lymphoma (FL)
Author(s)
Shaker Dakhil, MD, Robert Hermann, MD, Akiko Chai,
Date: 2011
MS, Deborah Hurst, MD, Gregg Fine, MD, and Paul
Richards, MD
Journal:
Poster presented at the 53rd American Society of Hematology Annual Meeting
Setting:
82 sites across the US
Sample Size: 451 patients
Experimental
MetaQuasiNonMeta-synthesis
analysis
experimental experimental Qualitative
Yes
No
Does this study apply to NHL patients?
If the answer is No, STOP here (unless there are similar characteristics)
Strength of Study Design
Yes
No
• Was the sample size adequate and appropriate?
Yes
No
• Were study participants randomized?
Yes
No
• Was there an intervention?
Yes
No
• Was there a control group?
Yes N/A
No N/A
• If there was more than one group, were groups equally
treated, except for the intervention?
Yes
No
• Was there adequate description of the data collection
methods?
Study Results
Yes
No
• Were results clearly presented?
Yes
No
• Was an interpretation/analysis provided?
Study Conclusions
Yes
No
• Were conclusion based on clearly presented results?
Yes
No
• Were study limitations identified and discussed?
Pertinent Study Findings and Recommendations:
Safety
• Pretreatment: acetaminophen, antihistamine and the oral steroid component of the patient’s
chemo – no additional steroids were permitted.
• The target duration of 90 minutes for the faster infusions was maintained over Cycles 2–8,
reflecting compliance with the protocol and demonstrating the feasibility of the schedule. (Of
1764 infusions administered at the faster rate the median infusion duration was 90 minutes.)
• The incidence of Grade 3/4 IRRs at Cycle 2 was low (1.1%) and the rate of IRRs decreased
with subsequent administrations
• Only 10 patients (2.8%) experienced Grade 3/4 IRRs during Cycles 2–8
• There were no fatal IRRs or fatal AEs on Days 1–2 at any cycle in this study, and there were
no unexpected events or acute fatal events associated with the faster infusion schedule
Recommendations
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Results from this study confirm that the 90-minute infusion schedule for rituximab is safe and feasible
in NHL patients who tolerate their first infusion administered at the standard rate and who do not have
significant cardiovascular disease or high circulating lymphocytes
Will the results answer the practice question?
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Evidence Level: IIIA
Article Title: Nursing Takes Time: Workload Associated With Administering Cancer Protocols
Author(s)
Johan de Raad, BSc, Kees van Gool, M.Ec, Marion Haas, Date: 2010
PhD, Philip Haywood, M.Ec, Margaret Faedo, PhD,
Gisselle Gallego, PhD, Sallie Pearson, PhD, and Robyn
Ward, PhD
Journal:
Clinical Journal of Oncology Nursing • Volume 14, Number 6
Setting:
New South Wales, Australia
Sample Size: 36 nurses
participated in six discussion
group sessions
Experimental
MetaQuasiNonMeta-synthesis
analysis
experimental experimental Qualitative
Yes
No
Does this study apply to NHL patients?
If the answer is No, STOP here (unless there are similar characteristics)
Strength of Study Design
Yes
No
• Was the sample size adequate and appropriate?
Yes
No
• Were study participants randomized?
Yes
No
• Was there an intervention?
Yes
No
• Was there a control group?
Yes N/A
No N/A
• If there was more than one group, were groups equally
treated, except for the intervention?
Yes
No
• Was there adequate description of the data collection
methods?
Study Results
Yes
No
• Were results clearly presented?
Yes
No
• Was an interpretation/analysis provided?
Study Conclusions
Yes
No
• Were conclusion based on clearly presented results?
Yes
No
• Were study limitations identified and discussed?
Pertinent Study Findings and Recommendations:
Resource Utilization
Article examines the nursing workload of administering alternative chemotherapy protocols as a
driver of costs. Data collection (focus groups with chemotherapy nurses and a survey of nurse unit
managers) was conducted to ascertain the time required to undertake chemotherapy-related tasks and
the sources of variability in six chemotherapy centers in New South Wales, Australia.
Four task types and time averages associated with administering chemotherapy:
1. patient education - 48 minutes during the first visit and 18.5 minutes thereafter
2. patient assessment - 20.3 minutes,
3. administration - 23 minutes,
4. patient communication - 24.2 minutes
Each patient received 3.3 hours of staff time (1.7 hours of direct contact time and 1.6 hours of
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noncontact time).
Recommendations (A major limitation of this study is that it is not specific to rituximab faster
infusion)
These data will allow healthcare decision makers and evaluators to predict the amount of nursing time
required to administer chemotherapy based on the characteristics of a wide range of chemotherapy
protocols.
Will the results answer the practice question?
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Evidence Level: IIIA
Article Title: Implications of IV monoclonal antibody infusion reaction for the patient, caregiver,
and practice: results of a multicenter study
Author(s)
Lee S. Schwartzberg, Edward J. Stepanski, Mark S.
Date: 2009
Walker, Susan Mathias, Arthur C. Houts & Barry V.
Fortner
Journal:
Support Care Cancer (2009) 17:91–98
Setting:
27 community US oncology sites
Sample Size: 161 were enrolled.
Of these, 90 were treated with
rituximab
Experimental
MetaQuasiNonMeta-synthesis
analysis
experimental experimental Qualitative
Does this study apply to NHL patients? N=72 (80% rituximab
Yes
No
pts)
If the answer is No, STOP here (unless there are similar characteristics)
Strength of Study Design
Yes
No
• Was the sample size adequate and appropriate?
Yes
No
• Were study participants randomized?
Yes
No
• Was there an intervention?
Yes
No
• Was there a control group?
Yes N/A
No N/A
• If there was more than one group, were groups equally
treated, except for the intervention?
Yes
No
• Was there adequate description of the data collection
methods?
Study Results
Yes
No
• Were results clearly presented?
Yes
No
• Was an interpretation/analysis provided?
Study Conclusions
Yes
No
• Were conclusion based on clearly presented results?
Yes
No
• Were study limitations identified and discussed?
Pertinent Study Findings and Recommendations:
Resource Utilization
A prospective multicenter study involving time and motion and activity sampling methods was
conducted among patients with cancer receiving their first outpatient infusion of cetuximab or
rituximab. Patients were observed from initiation of MoAb infusion to the end of the clinic visit. IRRs
were classified as absent, mild/moderate, and severe/life threatening. Staff time and costs were
estimated for preparation and administration of MoAb, other chemotherapy agents, and for
management of IRRs. Resource costs were compared across IR groups within each MoAb. IRRs
following rituximab administration are common and are associated with measurably increased costs of
care Among 161 patients enrolled, 39% of 90 patients on rituximab experienced IRs.
Treatment of patients who experienced IRs required more staff time (31–80% more time) and resulted
in higher human resource costs (increase of 17–65 US dollars) than patients who did not experience
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IRs. For rituximab patients, the staff time required for rituximab infusion was 164.6 min for patients
who had IRs and 123.3 min for those who did not and a statistically significant finding was mean
human resource costs ranging from $54 to $118 for no IR to mild/moderate IR: F (2, 6.448)=5.858,
p=.035 (mild/moderate > no IR).
Recommendations
The frequency of IRs suggests the importance of identifying clinical guidelines for intervention and
management. The methods used in this study could be employed for any direct comparison of
chemotherapy regimens that purports to examine treatment cost as an outcome.
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Evidence Level: IIIA
Article Title: The Impact of Infusion Reactions on Oncology Patients and Clinicians in the
Inpatient and Outpatient Practice Settings
Author(s)
Hilary H. Colwell, MPH, Susan D. Mathias, MPH, Nita H. Date: 2007
Ngo, MPH, Matthew Gitlin, PharmD, Z. John Lu, PhD,
Teresa Knoop, RN, MSN, AOCN
Journal:
Journal of Infusion Nursing, Vol. 30, No. 3, May/June 2007
Setting:
Inpatient and Outpatient Practice Settings
Sample Size: 202 nurses (99%
women)
Experimental
MetaQuasiNonMeta-synthesis
analysis
experimental experimental Qualitative
Yes
No
Does this study apply to NHL patients?
If the answer is No, STOP here (unless there are similar characteristics)
Strength of Study Design
Yes
No
• Was the sample size adequate and appropriate?
Yes
No
• Were study participants randomized?
Yes
No
• Was there an intervention?
Yes
No
• Was there a control group?
Yes N/A
No N/A
• If there was more than one group, were groups equally
treated, except for the intervention?
Yes
No
• Was there adequate description of the data collection
methods?
Study Results
Yes
No
• Were results clearly presented?
Yes
No
• Was an interpretation/analysis provided?
Study Conclusions
Yes
No
• Were conclusion based on clearly presented results?
Yes
No
• Were study limitations identified and discussed?
Pertinent Study Findings and Recommendations:
Nursing Practice
• Most nurses reported that administration with rituximab or paclitaxel resulted in the most
frequent infusion reactions (46% and 27%, respectively).
•

96% reported that Grade 3 or 4 infusion reactions were “very” or “extremely” disruptive for
patients, and most nurses indicated that Grade 3 or 4 infusion reactions were disruptive to the
nurses (80%).

•

95% agreed with the statement, “Infusion reactions can result in lost time and increased patient
anxiety”), with a greater proportion of outpatient nurses than inpatient nurses agreeing or
strongly agreeing with this statement (98% versus 90%, respectively; P ≤ .05).

•

Infusion reactions associated with parenteral monoclonal antibody treatments and
chemotherapy are disruptive and emotionally challenging for patients receiving the treatment
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and the nurses and staff at the institution or practice treating them.
Recommendations
• The results suggested that further awareness of infusion reaction management and education of
patients and clinicians are needed.
Will the results answer the practice question?
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Article Title: Oncology Nurses’ Perceptions About Involving Patients in the Prevention of
Chemotherapy Administration Errors
Author(s)
David L.B. Schwappach, MPH, PhD, Marc-Anton
Date: 2010
Hochreutener, MD, and Martin Wernli, MD
Journal:
Oncology Nursing Forum Vol. 37, No. 2, March 2010
Setting:
Outpatient oncology units of a community Sample Size: 11 actively
hospital in Switzerland
practicing oncology nurses
Experimental
MetaQuasiNonMeta-synthesis
analysis
experimental experimental Qualitative
Yes
No
Does this study apply to NHL patients?
If the answer is No, STOP here (unless there are similar characteristics)
Strength of Study Design
Yes
No
• Was the sample size adequate and appropriate? N=11
Yes
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• Were study participants randomized?
Yes
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• Was there an intervention?
Yes
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• Was there a control group?
Yes
N/A
No N/A
• If there was more than one group, were groups equally
treated, except for the intervention?
Yes
No
• Was there adequate description of the data collection
methods?
Study Results
Yes
No
• Were results clearly presented?
Yes
No
• Was an interpretation/analysis provided?
Study Conclusions
Yes
No
• Were conclusion based on clearly presented results?
Yes
No
• Were study limitations identified and discussed?
Pertinent Study Findings and Recommendations:
Nursing Practice
Oncology nurses perceive patient education in safety as a core element of their professional role and
are receptive to advancing their expertise in this area. Engaging patients was described as a challenge
and nurses acknowledged the diverse needs of patients and deliberately used different strategies to
involve patients in safety.
Recommendations
Oncology nurses should include patient involvement in error prevention given the reported positive
experiences.
Will the results answer the practice question?
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Article Title: Cytokine-Release Syndrome: Overview and Nursing Implications
Author(s)
Breslin, S
Date: 2007
Journal: Clinical Journal of Oncology Nursing • Supplement to Volume 11, Number 1 • CytokineRelease Syndrome
Systematic
Review

Clinical
Organizational (QI,
Expert opinion, case study,
Practice
QA, PT, financial data) literature review
Guidelines
Does this study apply to the population targeted for my practice
Yes
No
question?
If the answer is No, STOP here (unless there are similar characteristics)
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No
• Is the question clear?
Yes
No
• Was a rigorous peer-review process used?
Yes
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• Are search strategies specified, and reproducible?
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No
• Are search strategies appropriate to include all pertinent studies?
Yes
No
• Are criteria for inclusion and exclusion of studies specified?
Yes
No
• Are details of included studies (design, methods, analysis) presented?
Yes
No
• Are methodological limitations disclosed?
Yes
No
• Are the variables in the studies reviewed similar, so that studies can be
combined?
Clinical Practice Guidelines
Yes
No
• Were appropriate stakeholders involved in the development of this guideline?
Yes
No
• Are groups to which guidelines apply and do apply clearly stated?
Yes
No
• Have potential biases been eliminated?
Yes
No
• Were guidelines valid (reproducible search, expert consensus, independent
review, current, and level of supporting evidence identified for each
recommendation)?
Yes
No
• Are recommendations clear?
Organizational Experience
Yes
No
• Was the aim of the project clearly stated?
Yes
No
• Is the setting similar to setting of interest?
Yes
No
• Was the methodology adequately described?
Yes
No
• Were measures identified?
Yes
No
• Were results adequately described?
Yes
No
• Was interpretation clear and appropriate?
Individual expert opinion, case study, literature review
Yes
No
• Was evidence based in the opinion of an individual?
Yes
No
• Is the individual an expert in the topic?
Yes
No
• Is author’s opinion based on scientific evidence?
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• Is the author’s opinion clearly stated?
• Are potential biases acknowledged?
Pertinent Study Findings and Recommendations:

Yes
Yes

No
No

Safety
Article describes principles related to cytokine-release syndrome in patients receiving MoAbs:
•

•

•

When a MoAb binds to an antigen on the target cell, chemokines recruit monocytes,
macrophages, cytotoxic T cells, natural killer cells, and complement to the area. The immune
effector cells bind to the fragment crystallizable or constant portion of the antibody, targeting the
cell for destruction by phagocytosis and cytolysis.
When the cell is destroyed, cytokines are released into the circulation from the targeted cell as
well as immune effector cells that have been recruited The constellation of associated symptoms
is known as cytokine-release syndrome.
Massive cytokine-release syndrome is an oncologic emergency; special precautions are
necessary for patients at high risk.

Recommendations
1. Prior to administering any MOAB, nurses should be familiar with its toxicity profile, including
the potential for acute and delayed infusion-related side effects.
2. The need for specific pre-medications should be assessed.
a. For patients with circulating lymphocyte counts of 25,000/mm3 or higher, the addition of
corticosteroids and histamine-2 receptor antagonists to the usual pre-medications is
recommended.
b. Hospitalization of such patients for inpatient administration of medication and close
monitoring should be strongly considered
3. MOABs always should be administered piggy-back into the distal port of a main IV line and
never should be given as an IV bolus.
4. An infusion pump always should be used for administration. The first infusion should be
administered slowly. Subsequent infusions may be given more rapidly as tolerated and per
package instructions.
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Article Title: Managing Premedications and the Risk for Reactions to Infusional Monoclonal
Antibody Therapy
Author(s)

Chung, C

Date: 2008

Journal: The Oncologist;13:725–732 www.TheOncologist.com
Systematic
Review

Clinical
Organizational (QI,
Expert opinion, case study,
Practice
QA, PT, financial data) literature review
Guidelines
Does this study apply to the population targeted for my practice
Yes
No
question?
If the answer is No, STOP here (unless there are similar characteristics)
Systemic Review
Yes
No
• Is the question clear?
Yes
No
• Was a rigorous peer-review process used?
Yes
No
• Are search strategies specified, and reproducible?
Yes
No
• Are search strategies appropriate to include all pertinent studies?
Yes
No
• Are criteria for inclusion and exclusion of studies specified?
Yes
No
• Are details of included studies (design, methods, analysis) presented?
Yes
No
• Are methodological limitations disclosed?
Yes
No
• Are the variables in the studies reviewed similar, so that studies can be
combined?
Clinical Practice Guidelines
Yes
No
• Were appropriate stakeholders involved in the development of this guideline?
Yes
No
• Are groups to which guidelines apply and do apply clearly stated?
Yes
No
• Have potential biases been eliminated?
Yes
No
• Were guidelines valid (reproducible search, expert consensus, independent
review, current, and level of supporting evidence identified for each
recommendation)?
Yes
No
• Are recommendations clear?
Organizational Experience
Yes
No
• Was the aim of the project clearly stated?
Yes
No
• Is the setting similar to setting of interest?
Yes
No
• Was the methodology adequately described?
Yes
No
• Were measures identified?
Yes
No
• Were results adequately described?
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No
• Was interpretation clear and appropriate?
Individual expert opinion, case study, literature review
Yes
No
• Was evidence based in the opinion of an individual?
Yes
No
• Is the individual an expert in the topic?
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Safety
Monoclonal antibodies, like other infused agents, are associated with a risk for infusion reactions,
although for most, the incidence of severe events is rare. Improving risk assessment for infusion
reactions has become a compelling medical need.
Recommendations
• Patients with high circulating malignant cell counts are at risk for severe infusion reactions to
rituximab. Premedications are considered standard procedure for minimizing the risk for
infusion reactions.
• Because most infusion reactions with monoclonal antibodies occur after the first or second
infusion, the value of premedication on subsequent infusions may decrease.
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Journal: Clinical Journal of Oncology Nursing, Volume 14, Number 2 •
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Yes
No
• Have potential biases been eliminated?
Yes
No
• Were guidelines valid (reproducible search, expert consensus, independent
review, current, and level of supporting evidence identified for each
recommendation)?
Yes
No
• Are recommendations clear?
Organizational Experience
Yes
No
• Was the aim of the project clearly stated?
Yes
No
• Is the setting similar to setting of interest?
Yes
No
• Was the methodology adequately described?
Yes
No
• Were measures identified?
Yes
No
• Were results adequately described?
Yes
No
• Was interpretation clear and appropriate?
Individual expert opinion, case study, literature review
Yes
No
• Was evidence based in the opinion of an individual?
Yes
No
• Is the individual an expert in the topic?
Yes
No
• Is author’s opinion based on scientific evidence?
Yes
No
• Is the author’s opinion clearly stated?
Yes
No
• Are potential biases acknowledged?
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Pertinent Study Findings and Recommendations:
Safety
Safety assessments from six studies of rituximab used as a single agent in previously treated patients
with indolent non-Hodgkin lymphoma (Davis et al., 1999, 2000; Maloney et al., 1994; Maloney, GrilloLopez, Bodkin, et al., 1997; Maloney, Grillo-Lopez, White, et al., 1997; McLaughlin et al., 1998; Piro
et al., 1999) gave an incidence of infusion-related reaction in 77% (7% Grades 3–4) of patients
during the first infusion, 30% (2% Grades 3–4) during the fourth infusion, and 14% (no Grade 3–
4 events) during the eighth infusion. The reactions generally occurred within 30 minutes to two hours
after initiation of the infusion and resolved with slowing or interruption of the infusion and supportive
care.
Rituximab is associated with infusion reactions that are caused primarily by cytokine release rather than
true allergic reactions.
Recommendations
• Prompt and accurate documentation of the infusion event including accurate grading of the event
will enable the prescribing clinician to decide whether re-challenge is feasible and safe.
• Re-challenge may include the re-administration of antihistamines and corticosteroids, followed
by administration of the agent at a reduced rate.
Will the results answer the practice question?
Yes
No
Evidence Rating
Strength of
Level I
Level
Level
Level IV
Level V
Evidence
(Strong)
II
III
Quality of Evidence (check one)
High
Good
Low/Major flaw
(A)
(B)
(C)
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NON-RESEACH Appraisal
Evidence Rating: VB
Article Title: Ninety-Minute Rituximab Infusions Can Be Performed Safely in Non-Hodgkin's
Lymphoma
Author(s)
Alison Palkhivala
Date: 2007
Journal: Oncology Nursing Society 32nd Annual Congress: Abstract 2010. April 24-27, 2007.
Systematic
Review

Clinical
Organizational (QI,
Expert opinion, case study,
Practice
QA, PT, financial data) literature review
Guidelines
Does this study apply to the population targeted for my practice
Yes
No
question?
If the answer is No, STOP here (unless there are similar characteristics)
Systemic Review
Yes
No
• Is the question clear?
Yes
No
• Was a rigorous peer-review process used?
Yes
No
• Are search strategies specified, and reproducible?
Yes
No
• Are search strategies appropriate to include all pertinent studies?
Yes
No
• Are criteria for inclusion and exclusion of studies specified?
Yes
No
• Are details of included studies (design, methods, analysis) presented?
Yes
No
• Are methodological limitations disclosed?
Yes
No
• Are the variables in the studies reviewed similar, so that studies can be
combined?
Clinical Practice Guidelines
Yes
No
• Were appropriate stakeholders involved in the development of this guideline?
Yes
No
• Are groups to which guidelines apply and do apply clearly stated?
Yes
No
• Have potential biases been eliminated?
Yes
No
• Were guidelines valid (reproducible search, expert consensus, independent
review, current, and level of supporting evidence identified for each
recommendation)?
Yes
No
• Are recommendations clear?
Organizational Experience
Yes
No
• Was the aim of the project clearly stated?
Yes
No
• Is the setting similar to setting of interest?
Yes
No
• Was the methodology adequately described?
Yes
No
• Were measures identified?
Yes
No
• Were results adequately described?
Yes
No
• Was interpretation clear and appropriate?
Individual expert opinion, case study, literature review
Yes
No
• Was evidence based in the opinion of an individual?
Yes
No
• Is the individual an expert in the topic?
Yes
No
• Is author’s opinion based on scientific evidence?
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Yes
Yes

No
No

Barbara Rogers, CRNP, MN, AOCN, an adult hematology-oncology nurse practitioner at Fox Chase
Cancer Center in Philadelphia, Pennsylvania, agreed that rapid infusions of rituximab are highly
desirable, if safe, because most major cancer centers have more patients than they have treatment space.
Patient and Nurse Satisfaction
“Patients were pleased with shortened infusion times, more time away from [the] facility, [and] more
control and flexibility in [their] treatment scheduling."
Resource Utilization
Rituximab faster infusion”… will make a huge difference to practice to free up those [treatment]
chairs."
Recommendations
According to Rogers, before rituximab faster infusion becomes standard practice in the United States
more data is needed because of the large impact that faster infusion this will have on nursing practice
and resource utilization.
Will the results answer the practice question?
Yes
No
Evidence Rating
Strength of
Level I
Level
Level
Level IV
Level V
Evidence
(Strong)
II
III
Quality of Evidence (check one)
High
Good
Low/Major flaw
(A)
(B)
(C)
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NON-RESEACH Appraisal
Evidence Rating: VA
Article Title: Health Economic Analysis of the Burden of Infusion Reactions on Patients,
Caregivers, and Providers
Author(s)
Barry Fortner, PhD & Pamela Hallquist Viale, RN, MS, CS, Date: 2009
ANP, AOCNP
Journal: ONCOLOGY. Vol. 23 No. 2 Supplement
Systematic
Review

Clinical
Organizational (QI,
Expert opinion, case study,
Practice
QA, PT, financial data) literature review
Guidelines
Does this study apply to the population targeted for my practice
Yes
No
question?
If the answer is No, STOP here (unless there are similar characteristics)
Systemic Review
Yes
No
• Is the question clear?
Yes
No
• Was a rigorous peer-review process used?
Yes
No
• Are search strategies specified, and reproducible?
Yes
No
• Are search strategies appropriate to include all pertinent studies?
Yes
No
• Are criteria for inclusion and exclusion of studies specified?
Yes
No
• Are details of included studies (design, methods, analysis) presented?
Yes
No
• Are methodological limitations disclosed?
Yes
No
• Are the variables in the studies reviewed similar, so that studies can be
combined?
Clinical Practice Guidelines
Yes
No
• Were appropriate stakeholders involved in the development of this guideline?
Yes
No
• Are groups to which guidelines apply and do apply clearly stated?
Yes
No
• Have potential biases been eliminated?
Yes
No
• Were guidelines valid (reproducible search, expert consensus, independent
review, current, and level of supporting evidence identified for each
recommendation)?
Yes
No
• Are recommendations clear?
Organizational Experience
Yes
No
• Was the aim of the project clearly stated?
Yes
No
• Is the setting similar to setting of interest?
Yes
No
• Was the methodology adequately described?
Yes
No
• Were measures identified?
Yes
No
• Were results adequately described?
Yes
No
• Was interpretation clear and appropriate?
Individual expert opinion, case study, literature review
Yes
No
• Was evidence based in the opinion of an individual?
Yes
No
• Is the individual an expert in the topic?
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Yes
Yes
Yes

No
No
No

Review of literature regarding the specific burden, including tasks and associated costs, that IRs have on
the patient and caregivers, and application of this information to help manage IRs. The potential burden
that MoAb-induced IRs can have on both nurses and patients is reviewed to assist in guiding clinical
decisions.
Overall, severe infusion reactions associated with use of monoclonal antibodies (MoAb) resulted in
increased estimates of time spent by staff to manage the infusion reactions, which resulted in increased
human resource costs.
Of 76 patients who experienced a severe IR (Grades 3–5), 47 were treated with rituximab, 64% were
treated for non-Hodgkin’s lymphoma and 68% of rituximab patients received MoAb therapy as first-line
treatment. 55.3% of rituximab patients were pre-medicated with antihistamines and 61.7% were premedicated with acetaminophen. NOTE: premedication is recommended for all patients receiving
rituximab.
For the incidence of severe IRs, 87% of rituximab had Grade 3 IRs with 66% of rituximab IRs
occurring during the first administration of the agent. For Grade 4 reactions 83% of rituximab IRs
required hospitalization, with a mean hospitalization stay of 5 to 6 days.
Time and motion studies are suggested as a model for community oncology centers to assess the tasks
involved and the associated costs in treating IRs caused by therapies such as rituximab and help
community oncology centers to evaluate their intervention strategies for IRs that may have a significant
impact on centers with limited staff resources.
The incidence of an IR resulted in increased MoAb infusion times and staff time, leading to increased
human resource costs. Compared to patients not experiencing IRs, statistically significant increases in
staff time during infusion were observed in patients experiencing IRs. Prevention, including patient
education about IR risks, and proper management of IRs may minimize these expenses for patients and
families.
Will the results answer the practice question?
Yes
No
Evidence Rating
Strength of
Level I
Level
Level
Level IV
Level V
Evidence
(Strong)
II
III
Quality of Evidence (check one)
High
Good
Low/Major flaw
(A)
(B)
(C)
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Appendix C: Rituximab Faster Infusion Survey
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#
I

Question

110
Answer

This section asks questions about your demographics. Please indicate the best
response.

What is your current role?

1

What is the highest degree you have
achieved?

2

Which of the following best describes
your practice setting?

3

How many years have you been
practicing nursing?
4

Keith Dawson

Select one:
Nurse Practitioner
Clinical Nurse Specialist
Infusion Nurse
Clinical Trial Nurse
Other: (please specify)
Select one:
Diploma
Associates
Bachelor
Master
DNP
DNSc
PhD
Other (please specify)
(Check all that apply)
Academic Medical Center
Community Hospital
Physician Office/Infusion Center
Outpatient
Inpatient
Other (please specify)
Select one:
<1
1-5
6-10
11-15
> 15
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II
#
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The following questions ask about how innovativeness may influence nurses’
decisions to adopt evidence-based practices.

1

Question
I network with other nurses outside of my
work environment

2

I am considered an informal/formal leader Select one: never; seldom; sometimes; often;
in my work environment
almost always

3

Co-workers ask my opinion about new
ideas/practices

Select one: never; seldom; sometimes; often;
almost always

4

I try new ideas/practices when research
indicates its value

Select one: never; seldom; sometimes; often;
almost always

Unless I have seen a similar idea/practice
work in the past, I am reluctant to try
something new
I need encouragement from others before
doing something new

Select one: never; seldom; sometimes; often;
almost always

5
6

Answer
Select one: never; seldom; sometimes; often;
almost always

Select one: never; seldom; sometimes; often;
almost always

This section asks questions about your experience with rituximab infusions and
III
infusion reactions. Please indicate the best response.
Answer
# Question
Have you administered rituximab with
both the standard infusion according to
the Rituxan United States Package insert
Select one: Yes; No
(USPI) and a rituximab faster infusion
1 schedule?
Select one:
0
Approximately how many patients have
1-5
you treated with rituximab faster
6-10
infusion?
11-15
>15
2

3

How would you rate your overall
Select one: very positive; positive; neutral;
experience with rituximab faster infusion? negative; very negative; N/A

Keith Dawson
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This next section asks about the impact of rituximab faster infusion on nursing
practice. You will be shown a series of statements. Please indicate your level of
agreement with each statement. Please do not use the “not sure” option unless you
truly do not have an opinion.

IV
# Question

Answer

I find that the administration of rituximab
faster infusion did not impact my ability
to monitor patients for adverse events

Select one: agree strongly; agree somewhat;
not sure; disagree somewhat; disagree
strongly; N/A

Select one: agree strongly; agree somewhat;
not sure; disagree somewhat; disagree
strongly; N/A

2

I find that the shorter time associated with
the administration of rituximab faster
infusion does not impact the quality of
patient care compared to the rituximab
administered according to the current
USPI

Select one: agree strongly; agree somewhat;
not sure; disagree somewhat; disagree
strongly; N/A

3

My practice setting has specific
guidelines in place for the dosage of
antipyretics (i.e., acetaminophen,
antihistamine, and corticosteroids) for the
administration of rituximab

4

Rituximab faster infusion will improve
scheduling efficiency for infusion chair
time

Select one: agree strongly; agree somewhat;
not sure; disagree somewhat; disagree
strongly; N/A
Select one: Yes; No

5

My practice setting has specific
guidelines for monitoring vital signs for
rituximab faster infusion

1

If YES, please specify vital signs
monitored and schedule
6
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Select one:
Vital signs before infusion and at q15 minute
intervals until infusion completion.
Vital signs before infusion and at q30 minute
intervals until infusion completion.
Other schedule: (please specify)
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#

7

8

9

Question

Answer

My practice setting tracks quality metrics
to assess infusion reaction rates

Select one: Yes; No

My practice setting uses standing orders
or protocols to manage infusion reactions

Select one: Yes; No

Nurses at my practice setting educate
patients and their families about infusion
reactions

Select one: agree strongly; agree somewhat;
not sure; disagree somewhat; disagree
strongly

Nurses at my practice setting encourage
patients and their families to report
10 infusion reactions to clinicians

11

12

113

Select one: agree strongly; agree somewhat;
not sure; disagree somewhat; disagree
strongly

Nurses at my practice setting clearly and
accurately document infusion reactions

Select one: agree strongly; agree somewhat;
not sure; disagree somewhat; disagree
strongly

Grade 3 & 4 infusion reactions are
disruptive for nursing practice

Select one: agree strongly; agree somewhat;
not sure; disagree somewhat; disagree
strongly

Rituximab faster infusion increases the
likelihood of a patient experiencing an
infusion related reaction as compared to
administering rituximab with a standard
infusion rate according to the Rituxan
United States Package insert (USPI)

Select one: agree strongly; agree somewhat;
not sure; disagree somewhat; disagree
strongly

13
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V
#

Question
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Overall impression
Answer

What is your overall impression of the
process of the administration of rituximab
faster infusion as compared to
administering rituximab with a standard
infusion rate according to the Rituxan
United States Package insert (USPI)?

Select one: very demanding; somewhat
demanding; not sure; easy; very easy; N/A

1

2

3

4

Based on my present experience with the
administration of rituximab faster
Select one: agree strongly; agree somewhat;
infusion, I would recommend
agree; not sure; disagree somewhat; disagree
administration of rituximab faster infusion strongly
to patients
Would you agree that the administration
of rituximab faster infusion is safe?

Select one: agree strongly; agree somewhat;
agree; not sure; disagree somewhat; disagree
strongly

Overall I believe patients would prefer the
Select one: agree strongly; agree somewhat;
administration of rituximab faster infusion
agree; not sure; disagree somewhat; disagree
over rituximab administered according the
strongly
current USPI
Thank you for completing this questionnaire
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D1: Background and Demographic Characteristics of Nurses
Questionnaire items

Response
Percent*

Response
Count (n=25)

What is your current role?
Nurse Practitioner
0.0%
0
Clinical Nurse Specialist
22.7%
5
Infusion Nurse
36.4%
8
Clinical Trial Nurse
40.9%
9
Other (please specify): 3 Managers & 1 Educator
4
No Response
3
What is the highest level of school you have completed or the highest degree you
have received?
Diploma
4.0%
1
Associates
8.0%
2
Bachelor
68.0%
17
Master
16.0%
4
DNP
0.0%
0
DNSc
0.0%
0
PhD
4.0%
1
Other (please specify)
0
Which of the following best describes your practice setting?
Academic Medical Center
20.0%
5
Community Hospital
20.0%
5
Physician Office/Infusion Center
24.0%
6
Outpatient
32.0%
8
Inpatient
16.0%
4
Other (please specify): Governmental Agency
1
How many years have you been practicing nursing?
<1
0.0%
0
1-5
16.0%
4
6-10
8.0%
2
11-15
4.0%
1
> 15
72.0%
18
* Response percentage reflects responses to answer options only. Other entries are not
reflected in percentages
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D2: Innovativeness- Leadership
Questionnaire items

Response
Percent
I am considered an informal/formal leader in my work environment
Never
4.0%
Seldom
0.0%
Sometimes
12.0%
Often
32.0%
almost always
52.0%
Co-workers ask my opinion about new ideas/practices
Never
0.0%
Seldom
4.0%
Sometimes
8.0%
Often
56.0%
almost always
32.0%
I try new ideas/practices when research indicates its value
Never
0.0%
Seldom
0.0%
Sometimes
16.0%
Often
44.0%
almost always
40.0%
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Response
Count (n=25)
1
0
3
8
13
0
1
2
14
8
0
0
4
11
10
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D3: Innovativeness- Reliance on others
Questionnaire items

Response
Response
Percent
Count (n=25)
Unless I have seen a similar idea/practice work in the past, I am reluctant to try
something new
Never
12.0%
Seldom
48.0%
Sometimes
40.0%
Often
0.0%
almost always
0.0%
I need encouragement from others before doing something new
Never
24.0%
Seldom
36.0%
Sometimes
36.0%
Often
4.0%
almost always
0.0%
I network with other nurses outside of my work environment
Never
0.0%
Seldom
8.0%
Sometimes
20.0%
Often
48.0%
almost always
24.0%
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3
12
10
0
0
6
9
9
1
0
0
2
5
12
6
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E1: The Iowa Model of Evidence-Based Practice to Promote Quality Care

Used/Reprinted with permission from the University of Iowa Hospitals and Clinics and Marita
G. Titler, PhD, RN, FAAN. Copyright 1998. For permission to use or reproduce the model,
please contact the University of Iowa Hospitals and Clinics at (319)384-9098.
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E2: Rituximab Faster Infusion: Nurse Experience
Approximately how many patients have you treated with rituximab faster
infusion?

>15

38.9%

11-15

11.1%

6-10

11.1%

1-5

38.9%

0

0.0%

0.0%

10.0%

20.0%

30.0%

40.0%

50.0%

How would you rate your overall experience with rituximab faster infusion?

N/A

0.0%

very negative

0.0%

negative

0.0%

neutral

11.1%

positive

11.1%

very positive
0.0%
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77.8%
20.0%

40.0%

60.0%

80.0%

100.0%
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E3: Rituximab Faster Infusion Impact- Nursing Practice
I find that the administration of rituximab faster infusion did not impact my
ability to monitor patients for adverse events
N/A

0.0%

disagree strongly

5.6%

disagree somewhat

0.0%

not sure

0.0%

agree somewhat

11.1%

agree strongly

83.3%

0.0%

20.0%

40.0%

60.0%

80.0%

100.0%

Grade 3 & 4 infusion reactions are disruptive for nursing practice

disagree strongly

11.1%

disagree
somewhat

5.6%

not sure

0.0%

agree somewhat

22.2%

agree strongly

61.1%

0.0%

20.0%

40.0%

60.0%

80.0%

Nurses at my practice setting clearly and accurately document infusion
reactions
disagree strongly

0.0%

disagree somewhat

0.0%

not sure

0.0%

agree somewhat
agree strongly

16.7%
83.3%

0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0% 70.0% 80.0% 90.0%
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E4: Rituximab Faster Infusion Impact: Guidelines, Policies and Procedures
My practice setting has specific guidelines in place for the dosage of
antipyretics (i.e., acetaminophen, antihistamine, and corticosteroids) for the
administration of rituximab
N/A 0.0%
disagree strongly

0.0%

disagree somewhat

0.0%

not sure

0.0%

agree somewhat

5.6%

agree strongly

94.4%

0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0% 70.0% 80.0% 90.0%100.0%
My practice setting tracks quality metrics to assess infusion reaction rates
80.0%

66.7%

60.0%
33.3%

40.0%
20.0%
0.0%
Yes

No

My practice setting uses standing orders or protocols to manage infusion
reactions
100.0%
83.3%
80.0%
60.0%
40.0%
16.7%

20.0%
0.0%
Yes

No

My practice setting has specific guidelines for monitoring vital signs for
rituximab faster infusion
80.0%
61.1%
60.0%
38.9%

40.0%
20.0%
0.0%
Yes
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E5: Rituximab Faster Infusion Impact- Resource Utilization
Rituximab faster infusion will improve scheduling efficiency for infusion chair
time

N/A

0.0%

disagree strongly

0.0%

disagree somewhat

0.0%

not sure

0.0%

agree somewhat

22.2%

agree strongly

77.8%

0.0%

20.0%

40.0%

60.0%

80.0%

100.0%

If YES, please specify vital signs monitored and schedule

70.0%
60.0%
60.0%
50.0%
40.0%
40.0%
30.0%
20.0%
10.0%
0.0%
Vital signs before infusion and at q15 minute Vital signs before infusion and at q30 minute
intervals until infusion completion.
intervals until infusion completion.
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E6: Rituximab Faster Infusion Impact- Patients
Nurses at my practice setting educate patients and their families about infusion
reactions

disagree strongly

0.0%

disagree somewhat

0.0%

not sure

0.0%

agree somewhat

5.6%

agree strongly

94.4%

0.0%

20.0%

40.0%

60.0%

80.0%

100.0%

Nurses at my practice setting encourage patients and their families to report
infusion reactions to clinicians

disagree strongly

0.0%

disagree somewhat

0.0%

not sure

0.0%

agree somewhat

0.0%

agree strongly

100.0%

0.0%

20.0%

40.0%

60.0%

80.0%

100.0%

120.0%

Overall I believe patients would prefer the administration of rituximab faster
infusion over rituximab administered according the current USPI
disagree strongly

0.0%

disagree somewhat

0.0%

not sure

0.0%

agree
agree somewhat
agree strongly

11.1%
5.6%
83.3%

0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0% 70.0% 80.0% 90.0%
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E7: Rituximab Faster Infusion Impact- Safety
Rituximab faster infusion increases the likelihood of a patient experiencing
an infusion related reaction as compared to administering rituximab with a
standard infusion rate according to the Rituxan United States Package insert
(USPI)

disagree strongly

47.1%

disagree somewhat

35.3%

not sure

17.6%

agree somewhat

agree strongly
0.0%

10.0%

20.0%

30.0%

40.0%

50.0%

Would you agree that the administration of rituximab faster infusion is safe?

disagree strongly

0.0%

disagree
somewhat

0.0%

not sure

0.0%

agree

16.7%

agree somewhat

16.7%

agree strongly
0.0%
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E8: Overall Impression
What is your overall impression of the process of the administration of rituximab
faster infusion as compared to administering rituximab with a standard infusion
rate according to the Rituxan United States Package insert (USPI)?
N/A
very easy

38.9%

easy

55.6%

not sure
somewhat demanding
very demanding

5.6%

0.0%

10.0%

20.0%

30.0%

40.0%

50.0%

60.0%

Based on my present experience with the administration of rituximab faster
infusion, I would recommend administration of rituximab faster infusion to
patients
disagree strongly
disagree somewhat
not sure
agree
agree somewhat

22.2%
5.6%

agree strongly
0.0%
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E9: Monitor and Analyze Structure, Process and Outcome Data

Nursing

• Iden fy nurse early adopters within prac ce se ng (see Figure 10 – Part 1)
• Assess nurses’ overall impression about rituximab faster infusion (see Figure 10- Part 2)
• Pre and post implementa on during 30-day pilot

Prac ce

Guidelines.
Policies
Procedures

Resource
U liza on

Pa ents

Keith Dawson

• Track quality metrics to assess Infusion reac on rates
• Monitor incidence of Grade 3 or 4 IRRs at Cycle 2 and beyond
• Review your prac ce se ng’s guidelines for monitoring vital signs
• Review your prac ce se ng’s standing orders regarding management of infusion reac ons

• Track infusion chair turn-over rates
• Pre and post implementa on during 30-day pilot
• Review your prac ce se ng’s procedures for monitoring vital signs
• Consider alterna ve schedules (i.e. monitor vital signs before infusion and at 30 minute intervals un l rituximab
faster infusion comple on)

• On Cycle 1, Day 1 (standard infusion) and Cycle 2, Day 1 (faster infusion)
• Assess pa ent sa sfac on with rituximab standard infusion versus faster infusion using a standardized pa ent
sa sfac on tool
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E10: Innovativeness and Overall Impression Assessment Tool (Part 1)
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E10: Innovativeness and Overall Impression Assessment Tool (Part 2)
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